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Genes store life data and information in genetic language. In accordance with the 
Central Dogma, life data are located in DNA sequences in the format of genes and 
the information is transcribed into transient molecules of RNA and finally the coding 
RNAs are translated into proteins. But the role of RNAs is pivotal. In other words, 
gene regulation (including expression or suppression) is an amazing and vital process 
that is composed of two central networks; DNAs and RNAs. Today, the principal and 
fundamental role of RNA molecules is revealed and it is known that the regulation 
of genes is directly controlled by DNA and RNA molecules. The diversity of RNAs in 
different cells and in particular Eukaryotic cells explains the importance of RNAs in 
gene regulation.
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Gene regulation is one of the most interesting and incredible discussion topics in 
life sciences. Indeed, the process of gene regulation is linked to many biomolecules, 
different spatial configuration of genes, enzymes, and environmental factors.
Genes are worthy pearls within the organisms’ genomic treasure, which can be 
brightened in due course according to the needs of cells.
In recent years, by the progression of disciplines such as bioinformatics, computa-
tional biology, computational chemistry etc., our understanding of gene charac-
teristics and gene regulation has been extended and is closer to natural processes. 
The main reason for this progression is the availability of the created 3-dimensional 
illustrations and animations thanks to advanced computational technologies, online 
and offline databases, tools, and software.
When we go back several decades, only DNA molecules were the cornerstone of 
gene regulation. Indeed, the network of DNA molecules was regarded as the center 
of the gene regulation process. Today, this point of view has changed. In recent 
years, the process of gene regulation is known as a twin structured composition in 
which both RNA and DNA molecules have a pivotal role. In other words, the feature 
of gene regulation is simultaneously processed by the complex system of RNA and 
DNA networks.
Although in parallel with DNAs, RNAs have a pivotal role in prokaryotic gene 
regulation and this feature is much bolder in Eukaryotes than in bacteria. Due to 
this fact, the size of eukaryotic genomes is much larger than prokaryotes and there 
are numerous RNAs that act as coding and noncoding RNAs (ncRNAs).
For example, the small nuclear RNAs (snRNAs) in Eukaryotes, which are situated 
in the nucleus, have a key role in the process of splicing, which may lead to forma-
tion of spliceosomes. This example is known as a normal process in eukaryotes and 
it does not occur in prokaryotic bacteria. Moreover, the process of splicing, which 
directly affects gene expression, separates the stages of transcription and transla-
tion in eukaryotes while the lack of splicing process in bacteria leads to simultane-
ous transcription and translation phases.
There are many examples that show the abundance of treasures relating to coding 
and ncRNAs in eukaryotes, which have a key role in the process of gene regulation.
In this regard, the presence of small RNAs of interference RNAs (RNAi) is an 
important occurrence in the post-transcriptional process that may lead to suppres-
sion or silencing gene expression. Interestingly, there are huge numbers of RNAi 
molecules with different mechanisms in different organisms.
Despite limited information regarding RNAi molecules, it is known that they are 
vital molecules that affect the process of gene regulation by controlling and/or 
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determining the expression of the genes. The RNAi molecules act as gene silencers 
by translation inhibition and/or degradation of RNAs (mostly mRNAs).
All in all, the ncRNAs, rather than coding RNAs, contribute in the process of gene 
suppression, gene expression, and in toto, gene regulation. That’s why the RNA 
network, in parallel with the DNA network, contributes to gene regulation.
In this book, different authors from different countries have presented their invalu-
able knowledge. Each chapter has its individual scientific worth and importance. 
Therefore, I suggest to scientists who work in the fields of genes, molecular biology 
and genetics not to miss this practical information. This book contains worthy 












Gene Regulation, an RNA 
Network-Dependent Architecture
Payam Behzadi and Lernik Issakhanian
1. A historical background of genetics
Genetics is known as an old and ancient science that its origination goes back
to at least 7000 years ago. Iranians are one of the earliest pioneers in genetics from
ancient world. The brilliant Iranian (Persian) literature epic of Shahnameh edited 
by the Iranian shining star literate “Abolqasem Ferdowsi Toosi” is an invaluable
evidence to prove this claim. By the time and progression in biology, the super-
amazing molecule of DNA was discovered. Today, we know that the unique mol-
ecule of DNA involves the genetic and vital data within its bases as constitutional 
structures of nucleotides. Both eukaryotic and prokaryotic chromosomes are made
up of DNA molecules. In addition to DNAs, the role and importance of RNAs are
not lesser than DNAs [1].
In 1953, the interesting structure of DNA molecule with anti-parallel double-
helix architecture was recognized by Watson and Crick. In 1958, the hypothesis of
central dogma of molecular biology was published by Crick in which he described 
the translation of genetic language located on DNA into amino acid sequences of
protein by the transient molecule of RNA (mainly messenger RNA (mRNA)). The
primitive biological characteristics of mRNA were recognized in 1961, while these
properties regarding ribosomal RNA (rRNA) and transfer RNA (tRNA) molecules
were determined in the 1950s [2].
2. Central dogma
In accordance with central dogma of molecular biology, the genetic information
hidden in the format of gene can be expressed throughout two vital processes of
transcription (production of coding molecules of mRNA) and translation (in which
nucleotides are replaced by amino acids). The central dogma’s content involves
both eukaryotes and prokaryotes. In this regard, the RNA polymerase (RNAP) 
contributes in the process of transcription to produce mRNA molecules from DNAs. 
In the process of translation, ribosomes are also contributed. As it is known, the
eukaryotic processes of transcription and translation are separated; this separa-
tion is because of the presence of intron sequences among exons. Indeed, introns
were discovered in 1977 in eukaryotes which resulted in the recognition of their
localization among exon sequences. In other words, the arrangement of introns
was revealed as noncoding mosaics of introns among the coding mosaics of exons. 
Normally introns, dependent on the eukaryotic cell’s need, should be eliminated 
via the splicing process. The splicing process, which leads to the occurrence of the
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spliceosome, separates the direct connection between transcription and translation 
stages, while the bacterial system misses splicing process. Therefore, the processes 
of transcription and translation couple together in bacteria. Furthermore, the 
coupling system of transcription-translation is achieved via the functional enzyme 
complex of RNAP and ribosome which is known as expressosome in bacteria [2–4].
Amazingly, the ribozyme domains (e.g. small self-cleaving RNAs) are present 
in noncoding sequences of introns and untranslated regions (UTRs) (mostly in 
3′UTRs) [2, 5].
By the progression of knowledge and technology from the 1970s in the twentieth 
century, the importance of the role of RNA molecules increased more and more. 
Pre-mRNA molecules in eukaryotes which are known as heterogeneous nuclear RNA 
(hnRNA) have incredible role in gene regulation and expression. Different manners for 
the beginning of transcription, different patterns of splicing process, different lengths 
of poly-adenine tails and different patterns in RNA editing processes have direct effects 
on gene regulation and expression. Incredibly, the RNA molecules act as trans-acting 
factors that affect the processes of gene regulation and gene expression [6, 7].
These characteristics relating to RNAs support the RNA World Hypothesis 
(RWH). According to RWH which was proposed by Alex Rich, RNAs are bifunc-
tional biopolymers which can appear in two different levels of bioactivities including 
enzymatic activities (ribozymes) and as informational genetic language. However, 
the Urzymes hypothesis challenges RWH. Urzymes are the earliest generation of 
enzymes originated from protein superfamilies with a conserved nucleus [6, 8–10].
The progression of the Internet, computers and online/offline software and 
tools, bioinformatics and computational biology and chemistry gives us a new hori-
zon in association with gene, gene regulation, gene expression and gene structure. 
By the help of advanced knowledge and technology, now it is known that DNA 
molecules play their roles as CDs which are burned and contain cells’ software tools 
as genetic information which encode into RNAs and proteins [1, 11].
3. RNA molecules, RNA network and gene regulation
In recent years throughout very strong evidences, it has revealed that the RNA 
molecules are not only temporal and transient transcripts which are obtained from 
the genes, but also they act as pivotal modulators that mediate pre-transcriptional 
and posttranscriptional steps and have direct effect on gene regulation and gene 
expression processes. Also, RNA molecules play a key role in producing and trig-
gering vital signals within the wide web of genomic structure. Now, it is known that 
there are two main groups of coding RNA and noncoding RNA (ncRNA) molecules 
in which each of them has its own functions, structures and characteristics. The 
coding RNA molecules are those which can be translated into proteins, while the 
ncRNAs cannot be translated in proteins. According to previous studies, a large 
group of RNAs has no ability to be translated. And in mammals as an important 
group of eukaryotes, only less than 2% of the transcribed RNA molecules can be 
translated into protein molecules. So, the population of ncRNAs overpasses the 
population of coding RNAs [1, 2, 6, 12, 13].
RNAs are important allosteric molecules that regulate the processes of gene 
regulation and gene expression. The allosteric property of RNAs enables them to 
switch different pathways by regulation of genes to be expressed or silenced. A great 
cooperation among rRNAs, tRNAs, mRNAs and small nuclear RNAs (snRNAs) 
in the processes of eukaryotic transcription and translation explains the depth of 
the RNA roles within a cell. In addition, eukaryotes encompass small nucleolar 
RNAs (snoRNAs), too. snoRNAs with 60–300 nucleotide lengths are known as 
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intermediate size of ncRNAs. They have different roles including targeting a diver-
sity of RNA molecules such as mRNA. This property depicts the regulatory role of 
snoRNAs. In this regard, there is another group of snRNAs known as small Cajal 
body-specific RNAs (scaRNAs) located in Cajal bodies or coiled bodies (CBs). CBs 
are compact organelles which are recognized within the eukaryotic nuclei. The CBs 
are consisted of a mass of proteins including snRNPs and snoRNPs. scaRNAs and 
snoRNAs are significant molecules which contribute in processing and modification 
of other RNA molecules like mRNA, rRNA, tRNA and snRNA. Interestingly, rRNAs 
are remarkable molecules which constitute ribosomal peptidyl transferase site. This 
illustrates the important role of RNAs as ribozymes which contribute in activation 
of peptidyl transferring and constitution of peptide bonds within polypeptides. 
Today it is known that short ncRNAs (such as microRNAs (miRNAs), Piwi-
interacting RNAs (piRNAs), transcription initiation RNAs (tiRNAs)), promoter-
associated RNAs (PARs) (including promoter-associated small RNAs (PASRs), 
transcriptional start site-associated RNAs (TSSa-RNAs) and promoter upstream 
transcripts (PROMPTS)) and long noncoding RNAs (lncRNAs) (comprising 
large intergenic noncoding RNAs (lincRNAs), transcribed ultraconserved regions 
(T-UCRs), telomeric repeat-containing RNAs (TERRAs), etc.) have unique role in 
gene regulation and gene expression [1, 2, 6, 14–19].
In prokaryotes such as bacteria, a diversity of small RNAs (sRNAs) act as 
regulatory molecules. These molecules are contributed in gene regulation and 
gene expression. Moreover, the cis-acting sequences of regulatory RNAs which are 
known as riboswitches have an effective role on gene regulation. In addition, some 
special DNA sequences have been recognized in bacteria and archaea which are 
known as clustered regulatory interspaced short palindromic repeats (CRISPRs). 
CRISPERs are able to be transcribed. The processed CRISPR transcripts act as 
guide RNAs (gRNAs) which destruct the viral nucleic acids including RNA or DNA 
molecules [2].
4. The importance and the role of NCRNA molecules
The ncRNAs are divided into two groups of lncRNAs (with >200 nucleotide 
lengths) and small ncRNAs (sncRNAs) (with 20–35 nucleotide lengths). Among 
different types of sncRNAs, the miRNAs are well-studied RNAs. They belong 
to RNA interference (RNAi) members with the length of 19–24 nucleotides. 
Amazingly, >60% of the coding genes are regulated by miRNAs. In other words, 
these molecules contribute in posttranscriptional process by silencing the related 
genes by prevention of translation. Drosha and Dicer are key enzymes to manu-
facture a mature miRNA molecule. The linkage of a single-stranded miRNA with 
the members of Argonautes produces RNA-induced silencing complex (RISC). 
The RISC binds to its complementary sequence on the 3′UTR section of targeted 
mRNA. In addition to miRNA pathway, piRNA and siRNA pathways are mem-
bers of RNAi pathways. piRNAs (with about 30 nucleotide lengths) and siRNAs 
resembling miRNAs bind to Argonautes to produce RISCs which contribute in 
gene silencing process. However, miRNAs have genomic origination, while the 
siRNAs may have exo- or endogenous origination. The piRNAs are free dicer 
pathways which bind to PIWI proteins. The PIWI proteins are known as the subset 
of Argonautes. The complex of PIWI proteins and piRNAs contributes in transpo-
son repression via degradation of transcripts belonging to transposable elements 
(epigenetic regulation). Furthermore, the piRNAs mediate the DNA methylation 
too. The tiRNAs as members of sncRNAs with about 17 nucleotide lengths may act 
as transcriptional regulators [1, 13, 18, 20, 21].
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snoRNAs contribute in rRNA modification within the nucleolus. These modifi-
cations involve pseudouridylation and 2’-O-methylation of rRNAs to promote the 
integrity and rRNA folding. According to characterizations of secondary structure 
and common motifs, the snoRNAs are divided into two main families of box C/D 
and box H/ACA. Interestingly, the majority of snoRNA molecules are mostly 
expressed from housekeeping gene introns. The presence of abundance of snRNAs 
and scaRNAs support the rate of snRNA modification [2, 16, 18].
PASRs (with 22–200 nucleotide lengths), PROMPTs (with lesser than 200 
nucleotides in length) and TSSa-RNAs (with 20–90 nucleotide lengths) are catego-
rized within the intermediate ncRNAs in size and have not been studied well [18].
The lncRNAs are consisted of heterogeneous ncRNAs with the length of >200 
nucleotides. They are known as the dominant mammalian ncRNAs of transcrip-
tome. lncRNAs are recognized as effective eukaryotic ncRNAs with a wide range of 
functions. lncRNAs are involved in gene expression and gene regulation by regulat-
ing the posttranscriptional processes, epigenetic modifications, etc. [2, 18, 22].
In conclusion, we can claim that RNA molecules have a key role in molecular 
biology. In recent years, the sciences of bioinformatics, computational biology and 
computational chemistry have offered us a new promise regarding the importance 
of RNAs in association with gene regulation.
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Abstract
Studying the dysregulation of expression of glutamate receptors is crucial to 
better understand the mechanisms associated with cognitive disabilities in Down 
syndrome (DS) patients. By using data of microarray experiments previously 
deposited in GEO Dataset, we studied the expression of 26 glutamate receptor genes 
in DS brain samples since prenatal to adult age in several brain structures. Overall, 
our results showed a complexity in the expression of the genes which were depen-
dent mainly on the brain structure analyzed; especially, the hippocampus showed a 
different expression pattern. While in the general brain analysis the overexpressed 
genes were GRIN3A and GRIN2C, higher expression levels of GRM1, GRID2, and 
GRIK1 gene receptors were recorded in hippocampus. Our results suggest that the 
glutamatergic system in association with other neurotransmitter systems in the 
human brain would associate with glutamatergic receptor alterations to bring upon 
synaptic changes and cognitive deficits in DS models.
Keywords: glutamatergic system, gene expression, Down syndrome, brain, 
bioinformatics
1. Introduction
Down syndrome (DS) or trisomy 21 is the leading cause of genetically defined 
intellectual disability, developmental brain abnormalities, and congenital birth 
defects. The phenotypical features of this syndrome affect almost all body systems, 
including neurodevelopment and cognitive aspects [1, 2]. Brains of individuals with 
DS show decreased volume and reduced neuronal density in diverse areas includ-
ing the cortex, hippocampus, and cerebellum [3–7], leading to delayed cognitive 
progress in infancy and childhood and mild-to-moderate intellectual disability 
[8–11]. Also, during adulthood, there is a loss of cognitive abilities and the develop-
ment of Alzheimer’s disease (AD) by the fourth decade of life [12, 13]. Glutamate is 
the principal and main excitatory neurotransmitter in the body [14–16]. Glutamate 
receptors are classified into metabotropic—G-coupled protein receptors—and 
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ionotropic—ligand-gated ion channels [17–26]. Many studies have agreed that a 
major function of glutamate receptors is the modulation of synaptic plasticity, 
which is the ability of neurons to change its connections in response to a stimuli; 
this mechanism is thought to be vital for memory and learning processes. An 
increase or decrease in the number of ionotropic glutamate receptors on a postsyn-
aptic cell may lead to long-term potentiation or long-term depression of that cell, 
respectively [27–30].
According to Tan et al. [31], there is evidence that reduction in hippocampal 
glutamate concentrations is associated with improved cognitive function by modu-
lating glutamatergic neurotransmission in non-DS people with AD. Also, murine 
models of DS suggest that there is an imbalance between hippocampal inhibitory 
and excitatory inputs [9, 24], changes in the levels of the glutamate transporter and 
vesicular glutamate transporter 1 (VGLUT1) [25], and impairments in signaling 
mechanisms downstream of the N-methyl-D-aspartate (NMDA) receptor [26]. In 
this context, it can be put into consideration that malfunctions in the glutamate 
metabolism and the glutamatergic system are major contributors to cognitive 
abnormalities.
In recent studies, it has been shown that patients with DS present a diminution 
of glutamate and glutamatergic synapses. In the research made with mice by Kaur 
et al. [32], the results indicated a downregulation of hippocampal glutamate associ-
ated with behavioral impairments and intellectual disabilities. In this context, our 
study aimed to analyze the differential expression of 26 glutamate receptor genes 
in DS brain samples from prenatal patients to adult age in several brain structures. 
Overall, our result showed the complexity in the expression of the 26 glutamate 
receptors encoding genes. Also, a general overexpression in brain samples of 
GRIN3A and GRIN2C, and higher expression levels of GRM1, GRID2, and GRIK1 in 
hippocampus, in comparison with some structures of brain cortex. We hypothesize 
that disruption of glutamatergic brain gene expression would be a crucial early step 
in the pathogenesis of cognitive disability in DS.
2. Glutamate receptors and DS
Glutamate is known to be the main excitatory neurotransmitter in the brain and 
under normal physiological conditions, mediates learning and memory, as well as 
other integrating brain functions of higher order; however, it is also known that 
the pathological signaling of glutamate contributes to neuronal cell death. This 
neurotransmitter is released in the synapse after the depolarization of the presyn-
aptic neurons, and it is eliminated by means of the GLT transporter in astrocytes, 
in normal physiological conditions, glutamate elimination being rapid and neu-
roprotective [33]. Glutamate has action on ionotropic (iGluR) and metabotropic 
(mGluRs) receptors. The ionotropic GluRs are ion channels (voltage sensitive), 
integral membrane proteins composed by four large subunits that form a central ion 
channel pore [34]. Glutamate receptor subunits are modular structures that contain 
the following domains: the extracellular amino-terminal domain (ATD), the extra-
cellular ligand-binding domain (LBD), the transmembrane domain (TMD), and an 
intracellular carboxyl-terminal domain (CTD) [34].
These receptor subunits are proteins assembled into heterotetrameric or 
homotetrameric receptors, including the N-methyl-D-aspartate receptor (NMDA) 
consisting of the subunits GluN1, GluN2A, GluN2B, GluN2C, GluN2D, GluN3A, 
and GluN3B, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
with the subunits GluA1, GluA2, GluA3, and GluA4, and the Kainate receptors with 
the subunits GluK1, GluK2, GluK3, GluK4, and GluK5 that function as mediators of 
9
Temporal and Spatial Differential Expression of Glutamate Receptor Genes in the Brain…
DOI: http://dx.doi.org/10.5772/intechopen.82446
the rapid synaptic responses to glutamate, contrary to what happens with mGluRs 
where their activation by glutamate is sensitive to ligand binding and produces 
slower and longer modulating alterations in synaptic activity [33, 35–37]. NMDA 
receptors are present in high density within the hippocampus and the cerebral cor-
tex performing fundamental physiological and pathophysiological functions in the 
central nervous system [38], among which learning, memory, brain plasticity, and 
recovery of injuries stand out. In these brain structures, differential expression of 
these receptors is evidenced, where a change in their dynamics could contribute to 
changes in cognitive and synaptic function [39]. When treated in conjunction with 
AMPA, they are attributed an important role in plasticity and synaptic transmission 
in many postsynaptic membranes [35, 40], with the latter receptors participating in 
protein-protein interactions with scaffolding proteins, such as PICK1 and GRIP1, 
and the TARP accessory proteins that help in AMPA receptor traffic and present 
additional targets for regulation [37].
Metabotropic glutamate receptors are members of the superfamily of G protein-
coupled receptors. There are eight mGluR subtypes divided into three groups based 
on sequence homology, G-protein coupling specificity, and pharmacological profile. 
In general, mGluRs of group I and their interacting proteins have the ability to 
function as both neuroprotective and neurotoxic and have also been implicated in 
neurodegenerative diseases, especially mGluR5 [33]. On the other hand, members 
of group II act by inhibiting neuronal responses in rats according to the studies of 
Copeland et al. [41], which has been associated with the onset of cognitive deficit, 
a characteristic that can be observed in people with DS. About this syndrome, it 
should be noted that it has been associated with an imbalance of excitatory/inhibi-
tory neurotransmitter systems, as highlighted in studies of murine with DS where 
the presence of alterations in the activity of glutamatergic neurotransmission, 
mainly affecting ionotropic receptors, an event that has also been evidenced when 
studying the overexpression of HSA21 genes in DS [42].
3. Glutamatergic system, cognition, and DS: our main approach
The glutamatergic system of the brain is one of the two major amino acid 
systems, being the GABAergic system the major one. This system is very important 
for information processing in neuronal networks of the neocortex and hippocam-
pus in particular [43, 44], which is why we decided to analyze not only the brain 
as a whole, but the hippocampus apart. Also, this brain structure has been studied 
in several articles related to DS [3, 45–47] because of the significant functional 
repercussion in memory processes and intellectual potential that follows the poor 
hippocampal development presented by individuals with DS. Because the glutama-
tergic system is key in cognition processes such as memory and learning [48, 49], 
we consider that the deregulation of the glutamate receptors could be critical in the 
pathophysiology of DS, specifically in the neurodevelopmental and neurocognitive 
defects. This can be a starting point for developing therapeutic strategies aimed to 
reduce the effects of altered brain structures in individuals with DS.
3.1 Our methodological approach
Our initial approach was to analyze the expression of glutamate receptors—
ionotropic and metabotropic—(Table A1) in DS brain samples and compare it 
to euploid controls. In order to accomplish this goal, we calculated the values of 
expression for selected genes by using the log10 transformed expression values 
of a DNA microarray experiment whose registration code and free access in the 
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GEO database was GSE59630 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE59630), previously deposited by Olmos-Serrano et al. [50], which 
fitted the statistical significance sample size to obtain trustable information about 
the functional neurogenomics in DS. The microarray experiment selected included 
gene expression data of 47,000 probes from 58 postmortem brain samples of DS 
patients and 58 postmortem brain samples of healthy controls classified by gender 
(25 from females and 33 from males of each condition), age (from 16 prenatal 
weeks to 42 years old), and in 11 structures: dorsolateral prefrontal cortex (DFC), 
visual cortex (V1C), cerebellar cortex (CBC), orbitofrontal cortex (OFC), ventral 
frontal cortex (VFC), inferior temporal cortex (ITC), hippocampus (HIP), medial 
frontal cortex (MFC), somatosensory cortex (S1C), inferior parietal cortex (IPC), 
and superior temporal cortex (STC).
3.2 Functional analysis
The software Cytoscape 3.6 [51] was used for visualizing and analyzing the 
protein-protein interaction network among the selected human glutamate receptors 
encoding genes. We use the BIOGrid database to obtain protein interaction data 
of each one of the genes evaluated. Biological Networks Gene Ontology plugin—
BiNGO tool—[52] was used to search in which gene ontology (GO) categories are 
significantly overrepresented in a set of genes. A hypergeometric test was applied 
to determine which were the significantly represented categories (p-value <0.05); 
significant values were adjusted using the Bonferroni family wise error rate correc-
tion [53]. From network analyzer plugin of the Max Planck Institute Informatik, 
network topology parameters were calculated. Moreover, a genetic interaction 
network was made in GENEMANIA (https://genemania.org/).
3.3 Z-score transformation
Log2 data for each gene in the DNA microarray experiment was log10 trans-
formed and then used for the calculation of Z score [54]. Z scores were calculated 
by subtracting the mean log gene intensities (within a single experiment) from the 
log intensity data for each gene, and dividing that result by the SD of all measured 
log intensities, according to Eq. (1):
Z-score transformation:
  Z − score =    (Log intensity of G − mean log intensity G…Gn)     ___________________________________________________ Standard Deviation log G…Gn (1)
All Z-score values were normalized on a linear scale −3.0 < 0 > +3.0. In it, the 
corresponding gene is overexpressed if the value of Z-score is greater than zero and 
on contrary is under-expressed if its value is negative.
3.4 Multivariate statistical analysis
Nonparametric analyses for comparing median values of Z-score were per-
formed among gender and age variables between DS patients and healthy control. 
Wilcoxon signed-rank test was used to calculate the differences between medians 
of two samples. Hierarchical clustering analysis (HCA) was selected as a method 
of cluster analysis that seeks to build a hierarchy of clusters [55]. To perform the 
HCA, Euclidean distance was used as a measure of distance between DS and control 
samples of Z-score values in several structures of brain cortex; p < 0.05 was defined 
as a threshold. Moreover, principal component analysis (PCA) was employed as 
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a computational procedure for the classification of multiclass gene expression 
in brain cortex structures between DS and control samples per sex and age. All 
analyses were run in SPSS program version 22 [56].
4. Our results
4.1 Protein-protein interaction (PPI) network and gene interactions
The PPI network made in Cytoscape 3.6 with all ionotropic and metabotropic 
receptors had 142 nodes and 3 connected components (Figure 1). The proteins 
encoded by GRIA2 and GRIN2B had the highest amount of interactions (33 and 
30, respectively). GRIA2 gene encodes a subunit of the family of glutamate AMPA 
receptors; these types of receptors mediate fast excitatory synaptic transmission. 
GRIN2B is also a subunit but, in this case, of a NMDA receptor which are involved 
in brain development, synaptic plasticity, learning, and memory. The malfunction 
of these two genes has been previously associated to neurodevelopmental disorders 
characterized by intellectual disability and delayed development of speech and 
motor skills [57–59]. Here, it is important to highlight that the many connections 
they have among the glutamatergic system make them key proteins in the brain 
protein homeostasis. Among the biological processes ontology categories associated 
to the network, there was synaptic transmission (P-value Bonferroni 6.44E-17) and 
transmission of nerve impulse (P-value Bonferroni 1.20E-15).
On the other hand, the gene interaction network made in GENEMANIA showed 
that the physical interactions with the highest weight are GRIN2A-GRIN1 (9.40E-01), 
CACNG2-GRIA1 (8.66E-01), and GRIK1-GRIK2 (8.35E-01). The gene GRIN2A encodes 
a subunit of a subset of NMDA receptors called GluN2A, mainly expressed in regions 
in the brain involved in speech and language; this gene is consistently referred to in 
the literature as associated with speech disorders such as impaired intelligibility of 
Figure 1. 
PPI network made with glutamate receptors in Cytoscape 3.6. The receptors analyzed in this study are shown in 
red; the interactors are shown in yellow.
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conversational speech [60]. GRIN1, on the other hand, also encodes a subunit of NMDA 
receptors called GluN1, which, along with other members of this superfamily, plays a 
key role in memory and learning. According to Chen et al. [61], several mutations on 
this gene have been associated with neurodevelopmental disorders such as epilepsy, 
causing in some patients hypotonia and facial dysmorphisms. GRIK1 and GRIK2 
encode subunits of the kainite family of glutamate receptors, associated with behavior 
according to the GWAS Catalog (https://www.ebi.ac.uk/gwas/) and with intellectual 
disability [62].
4.2 Temporal and spatial gene expression in postmortem brains of DS patients
According to the temporal gene expression analysis made, there were no signifi-
cant differences among the DS brain samples and the control group (Figure 2). This 
is contrasting to the results obtained in other studies focused on mice like the article 
published by Zhao et al. [63] where they found a difference between older and 
younger organisms when measuring the expression of glutamate receptors; in their 
experiment, they found that NMDA receptor functions, receptor subunit composi-
tion, and/or the environment in which the receptor interacted were not the same in 
the old mice as in younger mice which may contribute to the memory decline seen 
during aging. Also, there is a study made on embryo chicks and 1-year-old chicks by 
Batista et al. [64] where they found that AMPA receptors exhibit temporal expres-
sion changes during tectal development of chicks that are compatible with such a 
role for glutamate. All the glutamate receptor subunits tested in that experiment—
GluR1, GluR2/3, and GluR4—showed an early expression suggesting some function 
in neurogenesis and migration.
The analysis of gene expression along the different brain structures (Table 1)  
showed an overexpression of the genes Glutamate Ionotropic Receptor NMDA 
Type Subunit 2C (GRIN2C) (Z-ratio 2.61) and the Glutamate Ionotropic Receptor 
NMDA Type Subunit 3A (GRIN3A) (2.94). GRIN2C encodes a subunit of an NMDA 
receptor, which is a subtype of ionotropic glutamate receptor involved in excitatory 
neurotransmission and in neuronal cell death. On the other hand, GRIN3A also 
encodes a subunit of a NMDA receptor and its deficit increases spine density and 
initiates synapse maturation and memory consolidation in early postnatal neurode-
velopment; both of these genes have been previously associated with schizophrenia. 
Figure 2. 
Z-score of glutamate ionotropic receptors per age-range of control and DS brain samples. Prenatal: 16–22 pre-
gestational weeks, 8 months to 1 year; teens: 12–18 years; and adults: 19–42 years.
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According to Ohi et al. [65], GRIN3A expression levels in the dorsolateral prefrontal 
cortex were elevated by approximately 30% in schizophrenia patients relative to 
controls, which suggest that aberrant enhanced GRIN3A function could be involved 
in the pathophysiology of schizophrenia and its cognitive impairments. Another 
study by Marco et al. [66] in patients with Huntington’s disease (HD) and in a 
mouse model of HD found something similar; a knockout of this gene decreased 
motor and cognitive dysfunction compared with no knockout and prevented stria-
tal atrophy and synaptic disconnection. These findings correlate with our results of 
human DS brains, leading us to propose that a similar process might take place in 
the pathophysiology of DS.
Gene symbol Z-score control Z-score DS ΔZ-score Z ratio*
Ionotropics
GRIA1 1.88 1.75 −0.12 0.93
GRIA2 2.28 2.21 −0.07 0.97
GRIA3 1.46 1.21 −0.25 0.83
GRIA4 0.97 0.79 −0.18 0.82
GRID1 0.45 0.32 −0.13 0.71
GRID2 0.71 0.76 0.05 1.07
GRIK1 0.58 0.74 0.16 1.28
GRIK2 1.36 1.36 0.00 1.00
GRIK3 0.91 0.59 −0.32 0.65
GRIK4 0.77 0.59 −0.18 0.77
GRIK5 0.91 0.85 −0.05 0.94
GRIN1 0.74 0.49 −0.24 0.67
GRIN2A 1.30 0.92 −0.37 0.71
GRIN2B 1.69 1.32 −0.38 0.78
GRIN2C 0.01 0.02 0.01 2.61
GRIN2D −0.45 −0.38 0.07 0.85
GRIN3A 0.02 0.07 0.05 2.94
GRINA 2.52 2.36 −0.16 0.94
Metabotropics
GRM1 0.29 0.20 −0.09 0.69
GRM2 0.27 −0.15 −0.43 −0.57
GRM3 1.66 1.54 −0.13 0.92
GRM4 0.28 0.33 0.06 1.20
GRM5 1.35 1.39 0.05 1.03
GRM6 −0.99 −0.96 0.03 0.97
GRM7 0.48 0.34 −0.15 0.69
GRM8 −0.52 −0.70 0.18 1.34
Log2 data for gene expression were obtained from the microarray experiment consigned in the GEO database with 
ID GSE59630, previously deposited by Olmos et al.
*Z-Ratio ≥ 1.50 is statistically significant; alpha 0.05.
Table 1. 
Differential expression values (Z-score and Z-ratio) of glutamate receptor encoding genes in the brain of 
patients with Down syndrome.
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Moreover, we decided to analyze the hippocampus apart because of its 
highly recognized importance not only in Down syndrome, but also in cogni-
tion processes, which are mainly regulated by the glutamatergic system [67]. 
Several studies have agreed that NMDA receptor (NMDAR)-dependent LTP or 
an LTP-like process in the hippocampus are the neural substrate for associa-
tive spatial learning and memory [68]. In this study, we found that this brain 
structure has some differences in gene expression when compared to the brain 
as a whole. While the general analysis of the brain showed an overexpression of 
the gene GRIN3A, at the hippocampus, we encountered an under-expression if 
this gene in DS samples. On the other hand, a gene that encodes the Glutamate 
Gene symbol Z-score control Z-score DS ΔZ-score Z ratio*
Ionotropics
GRIA1 2.15 2.25 0.10 1.04
GRIA2 2.48 2.35 −0.13 0.95
GRIA3 1.59 1.62 0.03 1.02
GRIA4 0.14 −0.07 −0.21 −0.49
GRID1 0.59 0.55 −0.04 0.93
GRID2 0.18 0.47 0.29 2.61
GRIK1 0.37 0.60 0.23 1.62
GRIK2 1.35 1.20 0.15 0.88
GRIK3 0.58 −0.19 −0.77 −0.32
GRIK4 0.96 0.95 −0.01 0.99
GRIK5 1.14 1.22 0.08 1.07
GRIN1 0.74 0.49 −0.25 0.67
GRIN2A 1.28 1.15 −0.13 0.90
GRIN2B 1.74 1.73 −0.01 0.99
GRIN2C 0.19 0.34 0.15 1.85
GRIN2D −0.56 −0.41 0.15 0.73
GRIN3A 0.35 −0.22 −0.57 −0.62
GRINA 2.40 2.28 −0.12 0.95
Metabotropics
GRM1 0.10 0.22 0.12 2.22
GRM2 0.10 −0.54 −0.64 −5.62
GRM3 1.68 1.30 −0.38 0.77
GRM4 0.12 0.05 −0.07 0.44
GRM5 1.51 1.62 0.11 1.07
GRM6 −0.96 −0.87 0.09 0.91
GRM7 0.71 0.51 −1.22 0.72
GRM8 −0.54 −0.75 −0.21 1.37
Log2 data for gene expression were obtained from the microarray experiment consigned in the GEO database with 
ID GSE59630, previously deposited by Olmos et al.
*Z-Ratio ≥ 1.50 is statistically significant; alpha 0.05.
Table 2. 
Differential expression values of glutamate receptor encoding genes in the hippocampus of patients with Down 
syndrome.
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Metabotropic Receptor 1 (GRM1) was overexpressed in the hippocampus 
(Z-ratio 2.22) as well as the Glutamate Ionotropic Receptor Delta Type Subunit 
2 (GRID2) (Z-score 2.61), the Glutamate Ionotropic Receptor Kainate Type 
Subunit 1 (GRIK1) (Z-score 1.62), and GRIN2C (Z-score 1.85). GRM1 is one 
of the most abundant mGluRs in the mammalian central nervous system and 
is present at particularly high levels in Purkinje cells [69]. There is plenty of 
evidence of its implication in diseases involving glutamatergic dysfunction and 
abnormal synaptic plasticity [70], which are known to be crucial mechanisms for 
cognitive processes. GRIK1 has also been reported as overexpressed in studies of 
DS; the study made on mice by Mazier [71] showed that GRIK mRNA levels are 
increased by more than 50% in different structures of the trisomic brain, which 
is coincidental with our findings (Table 2).
4.3  Principal component analysis (PCA) and hierarchical cluster analysis 
(HCA)
According to the PCA performed for the control samples, five principal 
components explained 80% of the cumulative variance; meanwhile, the PCA 
performed for the DS samples showed that six principal components explained 
83% of the cumulative variance. In Figure 3, we present the PCA for the two 
groups, where we found some differences in the clustering of genes when 
comparing the group samples, specifically in genes GRID2, GRM1, GRM4, and 
GRIK2 which were closely grouped in the PCA for controls. Also, even though 
the gene GRIK1 remained on the same position in both PCA, its association with 
GRIA1 changed from being separated in the control group, to be near each other 
in the DS group.
The HCA analysis produced a Heatmap that showed gene expression differences 
in the hippocampus (Figure 4), specifically in the genes Glutamate Ionotropic 
Receptor Kainate Type Subunit 3 (GRIK3) and GRIN3A which were under-
expressed in DS samples as mentioned previously. GRIK3 has not been related 
to DS in particular, but it has been widely studied for its association with schizo-
phrenia and major depression [72, 73]. Overall, the expression of the glutamate 
metabotropic receptors was especially high in the OFC in comparison to other brain 
structures.
Figure 3. 
Principal component analysis in 11 brain structures in DS brain samples and controls: dorsolateral prefrontal 
cortex (DFC), visual cortex (V1C), cerebellar cortex (CBC), orbitofrontal cortex (OFC), ventral frontal 
cortex (VFC), inferior temporal cortex (ITC), hippocampus (HIP), medial frontal cortex (MFC), 
somatosensory cortex (S1C), inferior parietal cortex (IPC), and superior temporal cortex (STC). Analyses 
were performed in SPSS v 22.0.
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is present at particularly high levels in Purkinje cells [69]. There is plenty of 
evidence of its implication in diseases involving glutamatergic dysfunction and 
abnormal synaptic plasticity [70], which are known to be crucial mechanisms for 
cognitive processes. GRIK1 has also been reported as overexpressed in studies of 
DS; the study made on mice by Mazier [71] showed that GRIK mRNA levels are 
increased by more than 50% in different structures of the trisomic brain, which 
is coincidental with our findings (Table 2).
4.3  Principal component analysis (PCA) and hierarchical cluster analysis 
(HCA)
According to the PCA performed for the control samples, five principal 
components explained 80% of the cumulative variance; meanwhile, the PCA 
performed for the DS samples showed that six principal components explained 
83% of the cumulative variance. In Figure 3, we present the PCA for the two 
groups, where we found some differences in the clustering of genes when 
comparing the group samples, specifically in genes GRID2, GRM1, GRM4, and 
GRIK2 which were closely grouped in the PCA for controls. Also, even though 
the gene GRIK1 remained on the same position in both PCA, its association with 
GRIA1 changed from being separated in the control group, to be near each other 
in the DS group.
The HCA analysis produced a Heatmap that showed gene expression differences 
in the hippocampus (Figure 4), specifically in the genes Glutamate Ionotropic 
Receptor Kainate Type Subunit 3 (GRIK3) and GRIN3A which were under-
expressed in DS samples as mentioned previously. GRIK3 has not been related 
to DS in particular, but it has been widely studied for its association with schizo-
phrenia and major depression [72, 73]. Overall, the expression of the glutamate 
metabotropic receptors was especially high in the OFC in comparison to other brain 
structures.
Figure 3. 
Principal component analysis in 11 brain structures in DS brain samples and controls: dorsolateral prefrontal 
cortex (DFC), visual cortex (V1C), cerebellar cortex (CBC), orbitofrontal cortex (OFC), ventral frontal 
cortex (VFC), inferior temporal cortex (ITC), hippocampus (HIP), medial frontal cortex (MFC), 
somatosensory cortex (S1C), inferior parietal cortex (IPC), and superior temporal cortex (STC). Analyses 




The glutamatergic system is closely related to cognition as it plays a key role in 
memory, working memory, and executive functions. It has been proven in mice with 
DS that a deregulation of this system can be crucial in both the neurodevelopmental 
and neurodegenerative components of DS. DS patients have intellectual disabilities 
with individual variability in the severity of both physiological and behavioral 
phenotypes. At the core of the intellectual disabilities is the phenomenon of synap-
tic plasticity, which is a functional change in the strength at the points of commu-
nication between neurons. Our results indicate hippocampal downregulation of the 
ionotropic receptor subunit GRIN3A (NMDA family), while in the general analysis 
of the brain, this gene was overexpressed. Other genes overexpressed in the hip-
pocampus were the metabotropic receptor GRM1, the ionotropic receptor subunit 
GRID2, and the kainate receptor subunit GRIK1. This deregulation might produce 
an alteration of both presynaptic and postsynaptic dysfunction at glutamatergic 
synapses, possibly contributing to behavioral impairments in patients with DS.
In general, our results suggest the existence of a fine regulation mechanism 
of gene expression networks, which is involved in the glutamatergic synaptic 
Figure 4. 
Heat map of glutamate receptor expression of 11 brain structures in DS brain samples and controls. Green color 
represents under-expression and red overexpression: dorsolateral prefrontal cortex (DFC), visual cortex (V1C), 
cerebellar cortex (CBC), orbitofrontal cortex (OFC), ventral frontal cortex (VFC), inferior temporal cortex 
(ITC), hippocampus (HIP), medial frontal cortex (MFC), somatosensory cortex (S1C), inferior parietal 
cortex (IPC), and superior temporal cortex (STC); performed in Cytoscape 3.6 software.
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system in several structures of brain from patients with DS. We hypothesize that 
disruption of glutamatergic brain gene expression would be a crucial early step in 
the pathogenesis of cognitive disability in DS. Moreover, our results suggest that 
glutamatergic system in association with other neurotransmitter systems in human 
brain, as GABA-mediated synaptic inhibition reported in other DS studies, might 
associate with glutamatergic receptor alterations to bring upon synaptic changes 
and cognitive deficits in DS models. Thus, glutamatergic receptor gene expression 
dysfunction may play a key role in the hippocampal pathogenesis of DS.
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system in several structures of brain from patients with DS. We hypothesize that 
disruption of glutamatergic brain gene expression would be a crucial early step in 
the pathogenesis of cognitive disability in DS. Moreover, our results suggest that 
glutamatergic system in association with other neurotransmitter systems in human 
brain, as GABA-mediated synaptic inhibition reported in other DS studies, might 
associate with glutamatergic receptor alterations to bring upon synaptic changes 
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dysfunction may play a key role in the hippocampal pathogenesis of DS.
Acknowledgements
The authors are grateful to the Universidad del Valle for the financing of 
some of the projects executed by LABIOMOL research group at the Department 
of the Physiological Sciences, School of Basic Sciences of the Faculty of Health, 
Universidad del Valle in Cali, Colombia. Within the document, the corresponding 
credits are given to both freely accessible bioinformatic platforms and the different 
computational tools used in the execution of the present study.
Conflict of interest





Subunit Official full name Locus
Ionotropic family
2890 GRIA1 GluA1 
(GluR1)
Glutamate ionotropic receptor 
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5q33.2
2891 GRIA2 GluA2 
(GluR2)
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4q32.1
2892 GRIA3 GluA3 
(GluR3)
Glutamate ionotropic receptor 
AMPA type subunit 3
Xq25
2893 GRIA4 GluA4 
(GluR4)
Glutamate ionotropic receptor 
AMPA type subunit 4
11q22.3
2894 GRID1 GluD1 
(GluRD1)
Glutamate ionotropic receptor 
delta type subunit 1
10q23.1-q23.2
2895 GRID2 GluD2 
(GlurD2)
Glutamate ionotropic receptor 
delta type subunit 2
4q22.1-q22.2
Kainate family
2897 GRIK1 GluK1 
(GluR5)
Glutamate ionotropic receptor 
kainate type subunit 1
21q21.3
2898 GRIK2 GluK2 
(GluR6)
Glutamate ionotropic receptor 
kainate type subunit 2
6q16.3
2899 GRIK3 GluK3 
(GluR7)
Glutamate ionotropic receptor 






Subunit Official full name Locus
2900 GRIK4 GluK4 
(KA-1)
Glutamate ionotropic receptor 
kainate type subunit 4
11q23.3
2901 GRIK5 GluK5 
(KA-2)
Glutamate ionotropic receptor 
kainate type subunit 5
19q13.2
NMDA family
2902 GRIN1 GluN1(NR1) Glutamate ionotropic receptor 
NMDA type subunit 1
9q34.3
2903 GRIN2A GluN2A 
(NR2A)
Glutamate ionotropic receptor 
NMDA type subunit 2A
16p13.2
2904 GRIN2B GluN2B 
(NR2B)
Glutamate ionotropic receptor 
NMDA type subunit 2B
12p13.1
2905 GRIN2C GluN2C 
(NR2C)
Glutamate ionotropic receptor 
NMDA type subunit 2C
17q25.1
2906 GRIN2D GluN2D 
(NR2D)
Glutamate ionotropic receptor 
NMDA type subunit 2D
19q13.33
116,443 GRIN3A GluN3A 
(NR3A)
Glutamate ionotropic receptor 
NMDA type subunit 3A
9q31.1
2907 GRINA GluN3B 
(NR3B)
Glutamate ionotropic receptor 




2911 GRM1 mGluR1 Glutamate metabotropic 
receptor 1
6q24.3




2912 GRM2 mGluR5 Glutamate metabotropic 
receptor 2
3p21.2




2914 GRM4 mGluR3 Glutamate metabotropic 
receptor 4
6p21.31
2916 GRM6 mGluR6 Glutamate metabotropic 
receptor 6
5q35.3
2917 GRM7 mGluR7 Glutamate metabotropic 
receptor 7
3p26.1
2918 GRM8 mGluR8 Glutamate metabotropic 
receptor 8
7q31.33
Information taken from the NCBI—Genbank platform.
Table A1. 
Description of glutamate receptors encoding genes.
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2918 GRM8 mGluR8 Glutamate metabotropic 
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Abstract
Signal transducers and activators of transcription (STATs) are a family of 
cytokine-regulated transcription factors, which serve the dual role of external 
signal transduction and transcriptional activation. The founding member of this 
family, STAT1, is involved in a plethora of cellular processes, including interferon-
dependent upregulation of various effector mechanisms in immune and non-
immune cells to control bacterial, fungal and parasitic infections. In this chapter, 
we discuss the principles of STAT1-driven gene expression and focus on the clinical 
phenotypes of various human STAT1 mutations. In particular, we highlight the sig-
nificance of sequence-specific DNA binding and intact nucleocytoplasmic shuttling 
for full transcriptional activation of interferon-driven target genes.
Keywords: signal transducer and activator of transcription (STAT), Janus kinase 
(JAK), DNA binding, cytokine signalling, gene expression, interferon, gain-of-
function mutation
1. Introduction
The origins of the seminal discovery of the intracellular signal transmitters 
mediating cytokine signalling now date back nearly three decades. In the late 
1980s, a group of researchers observed that signal transmission could be induced 
within minutes after stimulating cells with type I interferons (IFNs). Such speed, 
with which the signal generated at the plasma membrane-bound receptor was 
transduced to the nucleus, suggested the presence of only a few intermediate steps. 
Eventually, the only two players involved were identified, which are receptor-
associated Janus kinases (JAKs) and the signal transducers and activators of 
transcription (STATs) [1]. The STAT proteins comprise a family of evolutionary 
highly conserved transcription factors, which are thought to have evolved with the 
development of the first multicellular organisms [2, 3]. They are expressed in vari-
ous metazoan animal species, including nematodes, insects and vertebrates [4–9]. 
In mammals, seven different STAT proteins have been identified, namely STAT1, 
STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6. The STATs are differentially 
activated by a variety of almost 50 extracellular signalling molecules, including 
interferons, interleukins, growth factors and hormones [10] and are involved in 
a plethora of biological processes, including cell differentiation, proliferation, 
development, immunity and apoptosis [11]. STAT1, the founding member of this 
27
Chapter 3
Gene Activation by the Cytokine-
Driven Transcription Factor 
STAT1
Roswitha Nast, Julia Staab and Thomas Meyer
Abstract
Signal transducers and activators of transcription (STATs) are a family of 
cytokine-regulated transcription factors, which serve the dual role of external 
signal transduction and transcriptional activation. The founding member of this 
family, STAT1, is involved in a plethora of cellular processes, including interferon-
dependent upregulation of various effector mechanisms in immune and non-
immune cells to control bacterial, fungal and parasitic infections. In this chapter, 
we discuss the principles of STAT1-driven gene expression and focus on the clinical 
phenotypes of various human STAT1 mutations. In particular, we highlight the sig-
nificance of sequence-specific DNA binding and intact nucleocytoplasmic shuttling 
for full transcriptional activation of interferon-driven target genes.
Keywords: signal transducer and activator of transcription (STAT), Janus kinase 
(JAK), DNA binding, cytokine signalling, gene expression, interferon, gain-of-
function mutation
1. Introduction
The origins of the seminal discovery of the intracellular signal transmitters 
mediating cytokine signalling now date back nearly three decades. In the late 
1980s, a group of researchers observed that signal transmission could be induced 
within minutes after stimulating cells with type I interferons (IFNs). Such speed, 
with which the signal generated at the plasma membrane-bound receptor was 
transduced to the nucleus, suggested the presence of only a few intermediate steps. 
Eventually, the only two players involved were identified, which are receptor-
associated Janus kinases (JAKs) and the signal transducers and activators of 
transcription (STATs) [1]. The STAT proteins comprise a family of evolutionary 
highly conserved transcription factors, which are thought to have evolved with the 
development of the first multicellular organisms [2, 3]. They are expressed in vari-
ous metazoan animal species, including nematodes, insects and vertebrates [4–9]. 
In mammals, seven different STAT proteins have been identified, namely STAT1, 
STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6. The STATs are differentially 
activated by a variety of almost 50 extracellular signalling molecules, including 
interferons, interleukins, growth factors and hormones [10] and are involved in 
a plethora of biological processes, including cell differentiation, proliferation, 
development, immunity and apoptosis [11]. STAT1, the founding member of this 
Gene Regulation
28
family, is the major signalling molecule activated by IFN-α/β and IFN-γ and plays a 
pivotal role in mediating immune responses to infectious pathogens. It is essential 
for the direct activation of various immune effector genes, including those cod-
ing for microbicidal molecules, antiviral proteins, antigen-presenting molecules, 
phagocytic receptors, chemokines and cytokines [12]. Not surprisingly, humans 
expressing STAT1 variants with nonsense or missense mutations often exhibit an 
increased susceptibility to bacterial and viral infections.
2. Design principles of the JAK/STAT signalling pathway
STAT signalling is a paradigm of a ligand-induced pathway from cell surface 
receptors to the transcriptional machinery, thereby connecting extracellular signals 
to the regulation of eukaryotic gene expression. The activation of STAT proteins and 
their mechanisms of action are unique in many ways: (i) This pathway represents 
one of the first examples of direct signalling to the nucleus without the involvement 
of second messengers, (ii) post-transcriptional modification by tyrosine phosphor-
ylation is a hallmark feature of this pathway and, (iii) STATs make direct contacts 
with both membrane-bound receptors and DNA, thereby integrating cellular 
processes at the membrane to nuclear events. The basic model of STAT signalling 
depends on a cascade of tyrosine phosphorylation steps, as shown in Figure 1 [11]. 
Binding of the ligand to its cognate cell surface receptor triggers the dimerization or 
multimerization of the transmembrane receptor subunits. Conformational changes 
in the receptor complex bring the non-covalently attached Janus kinases (JAKs) 
into close spatial proximity to each other and allow their trans-phosphorylation on 
specific tyrosine residues. As a result, the JAKs are activated and, in turn, phosphor-
ylate specific tyrosine residues on cytoplasmic receptor domains, thereby creating 
docking sites for latent, cytoplasmic STAT molecules which bind through their 
src-homology-2 (SH2) domain. All mammalian STAT proteins bear a conserved 
signature tyrosine residue near their C-terminus, which becomes phosphorylated 
by the JAKs. Upon this modification, they dissociate from the receptor complex and 
immediately dimerise via reciprocal phosphotyrosine (pY)-SH2 domain interac-
tions. With the exception of STAT2, all human STAT proteins form homodimers. 
In addition, STATs are frequently engaged in heterodimer formation, for example, 
STAT1:STAT2 and STAT1:STAT3, and the amount of heterodimeric STATs depends 
on the nature and concentration of the activating ligands.
Due to their large protein size (~180 kDa for the STAT1 dimer), nuclear import 
of activated STATs requires a carrier-facilitated transport process through the 
nuclear core complex. Nuclear trafficking of tyrosine-phosphorylated STAT is 
mediated by importin-α proteins [13]. Tyrosine-phosphorylated STAT1 dimers 
are translocated as cargo proteins by a mechanism depending on importin 
α-5:importin-β1 and the small G protein Ran [14–16], whereas nuclear import of 
STAT3, STAT5 and STAT6 appears to be mediated primarily by interaction with 
other members of the protein family of karyopherins [17, 18]. Once in the nucleus, 
the STAT proteins act as classical transcription factors and bind to specific regula-
tory DNA sequences to activate or repress the transcription of their target genes. 
All members of the STAT family bind to a palindromic consensus motif termed 
gamma-interferon activated sequence (GAS) (5′-TTCN3GAA-3′). A notable excep-
tion is STAT2, which appears to be defective in DNA binding and instead associates 
with STAT1 and interferon-regulatory factor 9 (IRF9) in a ternary complex, which 
is called interferon-stimulated gene factor 3 (ISGF3) [19]. This transcriptionally 
active complex binds to a distinct direct repeat motif (5′-AGTTTCN2TTTC-3′) 
termed interferon-α-stimulated response element (ISRE).
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The kinetics of STAT-mediated gene transcription is strictly regulated in both 
the cytoplasmic and nuclear compartment. The inactivation of nuclear STAT 
proteins rapidly occurs following nuclear import and initiation of gene transcrip-
tion. This process has been best studied for the founding member of this family, 
STAT1. When not contacting DNA, STAT1 dimers undergo a conformational 
change, which results in the exposure of the critical phosphotyrosine residue at 
position 701 [20–23]. In this conformation, STAT1 is highly susceptible to dephos-
phorylation by the nuclear isoform of the T-cell protein tyrosine phosphatase 
(Tc45) [24–26]. It has been demonstrated that Tc45 induced dephosphorylation is 
a prerequisite for STAT1 to exit the nucleus [27]. As shown for STAT1 and STAT3, 
nuclear export is assisted by the exportin CRM1 (chromosome region maintenance 
1), which acts in a Ran-dependent manner [28–32]. Back in the cytosol, STATs can 
then participate in additional cycles of cytoplasmic re-activation, nuclear import 
Figure 1. 
Model of the interferon-γ-induced JAK/STAT signal pathway depicting the activation-inactivation cycle of 
STAT1. Binding of IFN-γ to the cell surface receptor triggers JAK-induced tyrosine phosphorylation of STAT1 
(1). Through spontaneous dissociation and reassociation, the activated STAT1 molecules constantly oscillate 
between the parallel and antiparallel dimer conformation (2). Phosphorylated dimers are translocated to the 
nucleus via binding to importins (3) where they bind to gamma-interferon activated sequence (GAS) motifs, 
potentially polymerise and induce gene transcription (4). After a conformational shift (5), antiparallel dimers 
are susceptible to dephosphorylation by the nuclear phosphatase Tc45 (6) and thereafter exit the nucleus (7).
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and inactivation, depending on the activation status of the cytokine receptor at the 
plasma membrane [33].
The rapid onset of JAK/STAT signalling is followed by subsequent decay, which 
includes the inactivation of cytokine receptors and JAKs, leading to a decrease in 
transcriptional activity. Apart from inactivation by nuclear phosphatases, STAT-
mediated signal transduction is tightly controlled by additional negative regulators. 
A well-studied inhibitory mechanism involves the upregulation of proteins, collec-
tively termed suppressors of cytokine signalling (SOCS) [34, 35]. These inhibitory 
proteins are components of a classical autoregulatory feedback loop, since most 
SOCS protein-encoding genes are well-established STAT targets. The SOCS proteins 
are generally expressed at low levels in resting cells but become rapidly induced 
after key stimulus exposure. The SOCS protein family comprises SOCS1–7 and the 
cytokine-inducible SH2-domain-containing protein (CIS), which counteract the 
JAK/STAT signalling by distinct ways. For example, SOCS1 binds to the catalytic 
subunit of the receptor-associated JAKs [36], while SOCS3 binds additionally to the 
receptor [37]. Both processes result in the inhibition of JAK activity and prevent 
further STAT activation. In contrast, CIS and SOCS2 have been proposed to sup-
press STAT activation by directly competing with STATs for binding to receptor 
docking sites [38, 39]. Another antagonistic mechanism involves protein inhibitors 
of activated STAT (PIAS) [40]. The family members of PIAS proteins are thought 
to directly bind to activated STAT dimers and show specificity as well as redun-
dancy in their action: PIAS1, PIAS3 and PIASx bind to STAT1, STAT3 and STAT4, 
respectively [41–43], while PIASy interacts with STAT1 [44]. They employ distinct 
mechanisms to repress STAT-dependent gene transcription, for example, PIAS1 
and PIAS3 block the DNA-binding activity to prevent STATs from binding to their 
target promoters. In contrast, PIASx and PIASy act as transcriptional co-repressors 
by recruiting other co-repressors, including histone deacetylases (HDACs) to stop 
the initiation of transcription. Interestingly, unlike other general negative regula-
tors, PIAS1 does not counteract the entire STAT1-induced gene repertoire but rather 
selectively inhibits only a subgroup of genes [45].
3. Structure and conformations of dimeric STATs
Mammalian STATs are composed of 750–850 amino acids, and their molecular 
weights range between 80 and 113 kDa. Biochemical, genetic and structural studies 
have revealed that STAT family members share the same modular architecture with 
six conserved functional domains organised in three independently folded struc-
tural units (Figure 2). The characteristic domains are the amino-terminal domain 
(ND) involved in protein-protein interactions and the core fragment which is com-
posed of a coiled-coil domain (CCD), DNA-binding domain (DBD), linker domain 
(LD) and SH2 domain, followed by the carboxy-terminal transactivation domain 
(TAD) [46, 47]. The N-domain and the transactivation domain are connected 
to the core fragment through short flexible linkers, of which the C-terminally 
Figure 2. 
Domain structure of STATs. STAT proteins are composed of conserved functional domains: ND: amino-
terminal domain, CCD: coiled-coil domain, DBD: DNA-binding domain, LD: linker domain, SH2: 
src-homology-2 domain, TS: phosphotyrosyl tail segment with the specific phosphorylation site, TAD: 
transactivation domain.
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located one harbours the conserved tyrosine residue in a stretch referred to as the 
phosphotyrosyl tail segment (TS). The overall similar structure and high conserva-
tion among the STAT proteins reflect similarities in activation, dimerization and 
DNA binding. The two most conserved structures are the N-domain and the SH2 
domain, both of which facilitate protein interactions, for example, dimerization 
[48], binding of the transcriptional co-activator CBP/p300 [49] or binding to the 
receptor. The transactivation domain is intrinsically unstructured and undergoes 
folding transition upon interaction with transcriptional co-activators [50]. Its 
residues vary considerably among the STAT family members affording divergent 
ways to activate individual target genes.
The first crystallographic analyses of STAT proteins revealed the structure of 
the core fragments of phosphorylated STAT1 and STAT3 lacking the N-domain 
and parts of the transactivation domain [46, 51] (Figure 3A–C). Details of the 
STAT-DNA interaction showed substantial similarities among the various members 
of the STAT protein family. The crystal structures of unphosphorylated STAT1 
(Figure 3D–F) and STAT5A dimers, as well as N-domain dimers of STAT4, greatly 
extended our general knowledge about the STAT proteins [48, 52, 53]. The original 
concept of latent STATs existing as cytoplasmic monomers [54] was soon chal-
lenged by a growing body of compelling evidence arguing for dimeric conforma-
tion prior to stimulus exposure. Crystallographic analyses of STAT1 and STAT5A 
Figure 3. 
Localisation of selected gain-of-function mutations within the STAT1 dimer. (A–C): Crystal structure of 
dimeric STAT1 in parallel conformation bound to DNA including the positions of some important site chains 
which, when mutated, cause an inborn error. The images show a ribbon diagram (A, B, D, E) or a molecular 
surface structure (C, F) of a STAT1 core fragment in parallel (A–C) and antiparallel dimer conformation 
(D–F), respectively. The enlarged section of the ribbon diagram demonstrates the spatial orientation of the 
residues F172 and T385 (coloured in magenta) in the interdimeric CCD:DBD interface. The selected GOF 
mutation sites F172, R274, F364 and T385 are marked in magenta. The STAT1 domains are coloured according 
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revealed unphosphorylated protomers self-assembled in a head-to tail alignment 
where the SH2 domains project from opposite ends of the dimer (Figure 3D–F). In 
this antiparallel conformation, the extended dimeric interface is formed by recipro-
cal interactions between the coiled-coil domain of one protomer and the DNA-
binding domain of its partner protomer (CCD:DBD) [52, 53].
Despite significant efforts, it is still unclear whether a stable dimerization of 
unphosphorylated monomers is common to all STATs. In addition to unphosphory-
lated homodimers, experimental data indicate the existence of STAT1:STAT2 and 
STAT1:STAT3 heterodimers prior to cytokine stimulation [55, 56]. In contrast to the 
antiparallel alignment in the absence of stimulation, activation of the JAK/STAT 
signal pathway results in the formation of dimers in parallel conformation, where 
the tyrosine-phosphorylated protomers arrange themselves in a highly symmetric 
head-to-head alignment held together by reciprocal phosphotyrosine (pY)-SH2 
domain interactions [46, 51] (Figure 3A–C). In this conformation, homotypic 
STAT dimers bind to DNA without the need of further protein-protein interac-
tions between the two protomers. It has been shown that tyrosine-phosphorylated 
STAT1 must first become dephosphorylated by nuclear phosphatases to be capable 
of leaving the nucleus to participate in additional rounds of a cytosolic reactivation 
and nuclear deactivation [27]. In the parallel conformation, the two phosphorylated 
tyrosine residues are buried in the opposing SH2 domain pockets, thereby protect-
ing STAT1 from being dephosphorylated. By the conformational rearrangement of 
the STAT1 dimer from a parallel to an antiparallel alignment, the critical phospho-
tyrosine residues are subjected to enzymatic dephosphorylation [23].
The molecular details of the transition between the parallel and antiparallel STAT1 
dimer conformation are still controversial. Initially, a model was proposed in which 
the N-terminal domains dimerise and keep the dimer partners held together, while 
the monomer’s core domains rotate around each other after phosphotyrosine-SH2 
disjunction [22]. The alternative mechanism, widely accepted today, describes the 
conformational reorientation as achieved by spontaneous dissociation of the tyrosine-
phosphorylated dimer into isolated monomers and their reassociation in antiparallel 
alignment [20, 57]. Studies indicate that STAT1 constantly oscillates between the two 
dimer conformations, and the abundance of each conformer is determined by the 
level of tyrosine phosphorylation. While unphosphorylated molecules exist in mono-
meric or dimeric, antiparallel conformation, there is a conformational equilibrium 
between phosphorylated dimers in parallel and antiparallel alignment [20].
4. Nucleocytoplasmic shuttling and transcriptional activity
Initially, STAT proteins were considered to function as latent transcription fac-
tors, which translocate to the nucleus and induce gene transcription exclusively in 
response to stimulus exposure. However, STAT1 and STAT3 were found to be present 
in the nucleus independent of tyrosine phosphorylation [33, 58, 59]. It became 
evident that, in contrast to phosphorylated STATs that are actively transported into 
the nucleus, the nuclear import of unphosphorylated STATs is facilitated by direct 
interactions with protein components constituting the nuclear pore complex [28]. 
This carrier-free translocation follows the concentration gradient across the nuclear 
envelope and, as facilitated diffusion, does not depend on metabolic energy. Thus, 
STAT proteins are constantly shuttling between the cytoplasmic and nuclear com-
partment, irrespective of their activation status. For some STAT family members, 
for example, STAT1, STAT2, STAT3 and STAT6, it has been shown that they play 
important roles in facilitating gene expression in the absence of stimuli and tyrosine 
phosphorylation [60–64]. In principle, unphosphorylated STAT1 is able to bind to 
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DNA, but its binding activity is 200-fold lower than that of activated STAT1 and, 
therefore, may not have any physiological relevance as a DNA-binding protein with-
out the recruitment of cofactors [20]. In line, unphosphorylated STAT1 was found in 
a complex with interferon-regulatory factor 1 (IRF1) to bind DNA at the promoter of 
the low molecular mass polypeptide 2 (LMP2) gene, which contains overlapping bind-
ing sites for both transcription factors [65]. The LMP2 gene encodes a component of 
the 20S proteasome and is induced by stimulation of cells with IFN-γ, but it is also 
expressed at low levels in the absence of cytokines [66]. From these experiments, it 
became clear that unphosphorylated STAT1 functions as a transcription factor, since 
it is directly responsible for constitutive LMP2 expression, but it is rapidly replaced 
by activated STAT1 dimers in response to IFN-γ stimulation [65].
More recently, it was reported that, in comparison to STAT1-deficient knockout 
animals, the pathogene Listeria monocytogenes grows less robustly in knockin mice 
expressing the Y701F mutant, which is unable to be tyrosine phosphorylated, indi-
cating a potential contribution of unphosphorylated STAT1 to innate antibacterial 
immunity [67]. Due to a positive autoregulatory loop of STAT1 signalling, expression 
of unphosphorylated STAT1 molecules is greatly increased after activation of STAT1. 
While the phosphorylation in response to IFNs lasts only for several hours, newly syn-
thesised unphosphorylated STAT1 persists for several days and results in enhanced 
signal transduction when the cells are thereafter re-exposed to low doses of IFN [68].
5. Serine phosphorylation and its effect on transcriptional activity
Apart from canonical, tyrosine phosphorylation STAT-driven transcription is also 
regulated by a number of posttranslational modifications, including serine phosphor-
ylation and sumoylation. All STATs except STAT2 can become phosphorylated at least 
at one serine residue embedded in a proline-rich sequence in the C-terminal transac-
tivation domain [69]. An evolutionary conserved phosphorylation site includes Ser 
727 in STAT1 and STAT3, Ser 721 in STAT4, Ser 725 in STAT5A, Ser 730 in STAT5B and 
Ser 756 in STAT6 [70, 71]. The maximal transcriptional activity and biological effects 
of at least STAT1, STAT3, and STAT4, and possibly also STAT5A, require both tyrosine 
and serine phosphorylation [70, 72–75]. This was corroborated by infection experi-
ments with mice unable to become phosphorylated at STAT1 Ser 727. Mice expressing 
STAT1 S727A died when challenged with high doses of the intracellular pathogen 
Listeria monocytogenes, whereas 80% of the wild-type littermates survived [72]. In the 
case of STAT1, a variety of signals cause the phosphorylation of Ser 727 and multiple 
candidate serine/threonine kinases have been implicated in this process. For example, 
interferons induce serine phosphorylation in addition to prior tyrosine phosphoryla-
tion. It was reported that, for canonical serine phosphorylation, STAT1 needs to be 
assembled into chromatin-bound transcriptional complexes and that the responsible 
kinase itself is similarly associated with DNA [76]. In this light, it was proposed that 
STAT1 recruits the cyclin-dependent kinase 8 (CDK8) to IFN-γ-driven target genes, 
which provides the kinase activity [77].
The need for serine phosphorylation to enhance transcriptional activity of 
STAT1 varies with different target genes and cell types, suggesting a complexity, 
which is not yet fully understood [72, 78]. It is hypothesised that STAT1 serine 
phosphorylation provides an extra supply of IFN-γ-induced gene products that are 
critical for full protection against pathogens [72]. Signals such as bacterial lipo-
polysaccharide (LPS) or mediators of inflammation and cellular stress exclusively 
stimulate the phosphorylation of serine 727, independent of tyrosine phosphoryla-
tion [79]. This modification takes place in the cytosol and involves the p38 mitogen-
activated protein kinase (MAPK) pathway [80, 81]. It has been proposed that the 
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revealed unphosphorylated protomers self-assembled in a head-to tail alignment 
where the SH2 domains project from opposite ends of the dimer (Figure 3D–F). In 
this antiparallel conformation, the extended dimeric interface is formed by recipro-
cal interactions between the coiled-coil domain of one protomer and the DNA-
binding domain of its partner protomer (CCD:DBD) [52, 53].
Despite significant efforts, it is still unclear whether a stable dimerization of 
unphosphorylated monomers is common to all STATs. In addition to unphosphory-
lated homodimers, experimental data indicate the existence of STAT1:STAT2 and 
STAT1:STAT3 heterodimers prior to cytokine stimulation [55, 56]. In contrast to the 
antiparallel alignment in the absence of stimulation, activation of the JAK/STAT 
signal pathway results in the formation of dimers in parallel conformation, where 
the tyrosine-phosphorylated protomers arrange themselves in a highly symmetric 
head-to-head alignment held together by reciprocal phosphotyrosine (pY)-SH2 
domain interactions [46, 51] (Figure 3A–C). In this conformation, homotypic 
STAT dimers bind to DNA without the need of further protein-protein interac-
tions between the two protomers. It has been shown that tyrosine-phosphorylated 
STAT1 must first become dephosphorylated by nuclear phosphatases to be capable 
of leaving the nucleus to participate in additional rounds of a cytosolic reactivation 
and nuclear deactivation [27]. In the parallel conformation, the two phosphorylated 
tyrosine residues are buried in the opposing SH2 domain pockets, thereby protect-
ing STAT1 from being dephosphorylated. By the conformational rearrangement of 
the STAT1 dimer from a parallel to an antiparallel alignment, the critical phospho-
tyrosine residues are subjected to enzymatic dephosphorylation [23].
The molecular details of the transition between the parallel and antiparallel STAT1 
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the N-terminal domains dimerise and keep the dimer partners held together, while 
the monomer’s core domains rotate around each other after phosphotyrosine-SH2 
disjunction [22]. The alternative mechanism, widely accepted today, describes the 
conformational reorientation as achieved by spontaneous dissociation of the tyrosine-
phosphorylated dimer into isolated monomers and their reassociation in antiparallel 
alignment [20, 57]. Studies indicate that STAT1 constantly oscillates between the two 
dimer conformations, and the abundance of each conformer is determined by the 
level of tyrosine phosphorylation. While unphosphorylated molecules exist in mono-
meric or dimeric, antiparallel conformation, there is a conformational equilibrium 
between phosphorylated dimers in parallel and antiparallel alignment [20].
4. Nucleocytoplasmic shuttling and transcriptional activity
Initially, STAT proteins were considered to function as latent transcription fac-
tors, which translocate to the nucleus and induce gene transcription exclusively in 
response to stimulus exposure. However, STAT1 and STAT3 were found to be present 
in the nucleus independent of tyrosine phosphorylation [33, 58, 59]. It became 
evident that, in contrast to phosphorylated STATs that are actively transported into 
the nucleus, the nuclear import of unphosphorylated STATs is facilitated by direct 
interactions with protein components constituting the nuclear pore complex [28]. 
This carrier-free translocation follows the concentration gradient across the nuclear 
envelope and, as facilitated diffusion, does not depend on metabolic energy. Thus, 
STAT proteins are constantly shuttling between the cytoplasmic and nuclear com-
partment, irrespective of their activation status. For some STAT family members, 
for example, STAT1, STAT2, STAT3 and STAT6, it has been shown that they play 
important roles in facilitating gene expression in the absence of stimuli and tyrosine 
phosphorylation [60–64]. In principle, unphosphorylated STAT1 is able to bind to 
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DNA, but its binding activity is 200-fold lower than that of activated STAT1 and, 
therefore, may not have any physiological relevance as a DNA-binding protein with-
out the recruitment of cofactors [20]. In line, unphosphorylated STAT1 was found in 
a complex with interferon-regulatory factor 1 (IRF1) to bind DNA at the promoter of 
the low molecular mass polypeptide 2 (LMP2) gene, which contains overlapping bind-
ing sites for both transcription factors [65]. The LMP2 gene encodes a component of 
the 20S proteasome and is induced by stimulation of cells with IFN-γ, but it is also 
expressed at low levels in the absence of cytokines [66]. From these experiments, it 
became clear that unphosphorylated STAT1 functions as a transcription factor, since 
it is directly responsible for constitutive LMP2 expression, but it is rapidly replaced 
by activated STAT1 dimers in response to IFN-γ stimulation [65].
More recently, it was reported that, in comparison to STAT1-deficient knockout 
animals, the pathogene Listeria monocytogenes grows less robustly in knockin mice 
expressing the Y701F mutant, which is unable to be tyrosine phosphorylated, indi-
cating a potential contribution of unphosphorylated STAT1 to innate antibacterial 
immunity [67]. Due to a positive autoregulatory loop of STAT1 signalling, expression 
of unphosphorylated STAT1 molecules is greatly increased after activation of STAT1. 
While the phosphorylation in response to IFNs lasts only for several hours, newly syn-
thesised unphosphorylated STAT1 persists for several days and results in enhanced 
signal transduction when the cells are thereafter re-exposed to low doses of IFN [68].
5. Serine phosphorylation and its effect on transcriptional activity
Apart from canonical, tyrosine phosphorylation STAT-driven transcription is also 
regulated by a number of posttranslational modifications, including serine phosphor-
ylation and sumoylation. All STATs except STAT2 can become phosphorylated at least 
at one serine residue embedded in a proline-rich sequence in the C-terminal transac-
tivation domain [69]. An evolutionary conserved phosphorylation site includes Ser 
727 in STAT1 and STAT3, Ser 721 in STAT4, Ser 725 in STAT5A, Ser 730 in STAT5B and 
Ser 756 in STAT6 [70, 71]. The maximal transcriptional activity and biological effects 
of at least STAT1, STAT3, and STAT4, and possibly also STAT5A, require both tyrosine 
and serine phosphorylation [70, 72–75]. This was corroborated by infection experi-
ments with mice unable to become phosphorylated at STAT1 Ser 727. Mice expressing 
STAT1 S727A died when challenged with high doses of the intracellular pathogen 
Listeria monocytogenes, whereas 80% of the wild-type littermates survived [72]. In the 
case of STAT1, a variety of signals cause the phosphorylation of Ser 727 and multiple 
candidate serine/threonine kinases have been implicated in this process. For example, 
interferons induce serine phosphorylation in addition to prior tyrosine phosphoryla-
tion. It was reported that, for canonical serine phosphorylation, STAT1 needs to be 
assembled into chromatin-bound transcriptional complexes and that the responsible 
kinase itself is similarly associated with DNA [76]. In this light, it was proposed that 
STAT1 recruits the cyclin-dependent kinase 8 (CDK8) to IFN-γ-driven target genes, 
which provides the kinase activity [77].
The need for serine phosphorylation to enhance transcriptional activity of 
STAT1 varies with different target genes and cell types, suggesting a complexity, 
which is not yet fully understood [72, 78]. It is hypothesised that STAT1 serine 
phosphorylation provides an extra supply of IFN-γ-induced gene products that are 
critical for full protection against pathogens [72]. Signals such as bacterial lipo-
polysaccharide (LPS) or mediators of inflammation and cellular stress exclusively 
stimulate the phosphorylation of serine 727, independent of tyrosine phosphoryla-
tion [79]. This modification takes place in the cytosol and involves the p38 mitogen-
activated protein kinase (MAPK) pathway [80, 81]. It has been proposed that the 
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biological relevance of serine phosphorylation is to prime STAT1 for an increased 
transcriptional response once IFN-γ provides the stimulus for tyrosine phosphory-
lation [78], as observed for macrophage activation.
An important paper from the Vinkemeier lab demonstrated that the activity of 
STAT1 is inhibited by conjugation to small ubiquitin-like modifier (SUMO), which 
is added to Lys 703 [82]. Although only a small fraction of the intracellular, unphos-
phorylated STAT1 pool is sumoylated, the modification by SUMO interferes with 
the formation of paracrystalline arrays in the nucleus, which sequester activated 
STAT1 molecules. SUMO conjugation diminishes the activity of STAT1 by interfer-
ence with tyrosine phosphorylation and, in addition, solubilizes the highly dynamic 
paracrystals in cytokine-stimulated cells [83].
6. Mechanisms of STAT1 DNA binding
Sequence-specific DNA binding of STAT proteins is a prerequisite for their 
function as cytokine-driven transcriptional regulators. STATs interact with high-
affinity binding sites on DNA through their DNA-binding domain, which shows the 
general architecture of an immunoglobulin fold [46, 47]. The crystal structure of 
DNA-bound STAT1 revealed that the transcription factor engages in several inter-
actions with the phosphodiester backbone of the DNA, but makes relatively few 
base-specific contacts, for example, through the residues Asp 460 and Lys 336 in 
the major and through Glu 421 in the minor groove [46]. Each STAT protomer binds 
to a half-site of a palindromic consensus motif termed gamma-interferon activated 
sequence (GAS). STAT1, STAT3, STAT4 and STAT5 bind to half-sites spacing two or 
three base pairs (5′-TTCN2-3GAA-′3), while STAT6 favours a four nucleotide spacer 
within the palindrome [84, 85]. The nucleotides between and around the core 
palindrome impart some level of specificity.
The implication of impaired DNA-binding activity became evident, when STAT1 
mutants were engineered by substituting numerous residues within the DNA-binding 
domain that potentially make contacts with the phosphodiester backbone of the 
DNA. The introduction of positive, negative or neutral charges was intended to 
increase or reduce electrostatic interactions between STAT1 and DNA, respectively. 
A STAT1 mutant termed STAT1 DNAminus, in which negative charges were introduced 
by substituting aspartic acid (Asp) for valine (Val) at position 426 (Val426Asp) and 
threonine at position 427 (Thr427Asp), was normally tyrosine phosphorylated in 
response to IFN-γ but essentially lost its DNA-binding activity [27]. The STAT1 
DNAminus mutant was highly susceptible to inactivation by the nuclear phosphatase 
Tc45 and failed to accumulate in the nucleus. In contrast, the mutant STAT1 DNAplus 
(Thr327Arg; Val426His; Thr427His) was capable of strongly binding to both specific GAS 
sites and nonspecific DNA sequences with nearly equal affinity. This mutant lost its 
discrimination for GAS sites and, due to its hindered dissociation from DNA, resisted 
dephosphorylation, resulting in prolonged nuclear accumulation [27]. These and 
additional experiments indicated that DNA binding determines the accumulation of 
STAT1 in the nucleus. This assumption was corroborated by the finding that high-
affinity DNA binding reduces the dissociation rate of STAT1 dimers from DNA and 
impairs the interdimeric exchange of their protomers in the presence of DNA [57].
In contrast to STAT1 DNAplus, substitution of two glutamic acid residues 
(Glu411Ala; Glu421Lys) generates a double mutant, which maintains the discrimina-
tion between GAS and nonspecific sites. However, STAT1-DNA complexes are stabi-
lised independent of the nucleotide sequence, leading to persistent and enhanced 
tyrosine phosphorylation and prolonged nuclear accumulation [86]. The presence 
of negatively charged residues at these positions is critical for the release of STAT1 
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from DNA. IFN-γ-induced expression of reporter genes and endogenous target 
genes is dramatically reduced in cells expressing STAT1 DNAplus, STAT1 Glu411Ala 
or STAT1 Glu421Lys [27, 86]. In summary, these data revealed the significance 
of sequence-specific DNA binding and fast dissociation from DNA for efficient 
STAT1-mediated gene regulation. An impaired dissociation of STAT1 from genomic 
DNA not only interferes with the continuous search for GAS sites but also prevents 
fast nucleocytoplasmic shuttling and full transcriptional activity of STAT1.
Early studies on the DNA binding of STATs revealed that their binding sites 
can extend over two or more adjacent consensus motifs and that activated STAT1, 
STAT3, STAT4 and STAT5 dimers can interact in homotypic fashion to polymerise on 
such DNA sequences, that is form tetramers or even higher order oligomers [48, 87–
91]. GAS motifs linked in tandem orientation have been identified in various STAT-
driven target genes, including, for example, those encoding IFN-γ [90], interleukin 
2 receptor α (IL-2Rα) [87, 88], perforin [92], cytokine-inducible SH2-containing 
protein (CIS) [93], α2-macroglobulin (α2-M) [91], and glycosylation-dependent cell 
adhesion molecule 1 (GlyCam1) [94]. The synergistic recognition of DNA, generally 
referred to as cooperative DNA binding, is mediated by the conserved N-terminal 
domain of the STAT proteins. It was shown that deletion or mutation of the STAT 
N-terminus abolishes cooperative dimer-dimer interactions [48, 89–91, 95].
Analysis of the crystal structure of the N-domain dimer has indicated an exten-
sive interface involving interactions between hydrophobic residues [96]. Targeted 
mutagenesis has revealed an orthologue residue (Phe 77 in STAT1 and Phe 81 in 
STAT5A/B, respectively) as physiologically most relevant for the oligomerisation 
of STAT proteins [95, 96]. Substitution of alanine for the critical phenylalanine in 
STAT1 does not overtly affect DNA binding on a single GAS site in response to IFN-γ 
but severely impairs tetramerisation [95, 97]. The cooperative binding of STAT1 
dimers strongly increases their DNA-binding affinity [89]. Such interactions do not 
require high-affinity GAS sites linked in tandem orientation. In vitro studies have 
revealed the recruitment of multiple STAT1 dimers to a single GAS site adjacent to 
low-affinity or even GAS-unrelated sequences [95]. Thus, N-domain interactions 
of DNA-bound STAT1 molecules greatly expand the repertoire of potential STAT1-
regulated IFN-γ target genes. An in silico analysis revealed that although single GAS 
sites frequently occur in the mouse genome, GAS sites linked in tandem orienta-
tion are rare and may not be enriched in IFN-γ target genes [97]. Paradoxically, a 
genome-wide transcriptional analysis revealed that STAT1-mediated cooperative 
DNA binding is indispensable for IFN-γ signalling, since the IFN-γ response is 
essentially lost in murine cells expressing the STAT1 F77A mutant [97]. Furthermore, 
cooperativity-deficient STAT1 F77A showed a pervasive promoter recruitment defect 
at GAS-containing IFN-γ-driven but not IFN-α/β-driven genes. It has, therefore, 
been proposed that STAT1 tetramerisation or polymerisation originates from a GAS 
site and then proceeds with loose additional requirements for adjacent sequences 
[97]. Infection experiments have highlighted the physiological relevance of STAT1 
tetramerisation. Listeria monocytogenes infection of STAT1 F77A-expressing mice 
revealed a severe defect in antibacterial immunity. The STAT1 cooperativity-defi-
cient animals succumbed more easily than their wild-type littermates [97].
The crystal structure of the unphosphorylated STAT1 dimer indicates that the 
dimerisation interface is composed of the phenylalanine residue 172 in the coiled-
coil domain of one protomer, which reciprocally is inserted into a pocket in the 
DNA-binding domain of its partner molecule. This pocket is created by the residues 
Q340, L383, G384, T385, H406, L407 and Q408 [52]. Several GOF mutations have 
been identified at this interdimeric interface [98, 99]. Studies on the molecular 
basis of these point mutations underscore the paramount importance of the con-
formational shift for STAT1-driven gene expression [98]. The critical phenylalanine 
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biological relevance of serine phosphorylation is to prime STAT1 for an increased 
transcriptional response once IFN-γ provides the stimulus for tyrosine phosphory-
lation [78], as observed for macrophage activation.
An important paper from the Vinkemeier lab demonstrated that the activity of 
STAT1 is inhibited by conjugation to small ubiquitin-like modifier (SUMO), which 
is added to Lys 703 [82]. Although only a small fraction of the intracellular, unphos-
phorylated STAT1 pool is sumoylated, the modification by SUMO interferes with 
the formation of paracrystalline arrays in the nucleus, which sequester activated 
STAT1 molecules. SUMO conjugation diminishes the activity of STAT1 by interfer-
ence with tyrosine phosphorylation and, in addition, solubilizes the highly dynamic 
paracrystals in cytokine-stimulated cells [83].
6. Mechanisms of STAT1 DNA binding
Sequence-specific DNA binding of STAT proteins is a prerequisite for their 
function as cytokine-driven transcriptional regulators. STATs interact with high-
affinity binding sites on DNA through their DNA-binding domain, which shows the 
general architecture of an immunoglobulin fold [46, 47]. The crystal structure of 
DNA-bound STAT1 revealed that the transcription factor engages in several inter-
actions with the phosphodiester backbone of the DNA, but makes relatively few 
base-specific contacts, for example, through the residues Asp 460 and Lys 336 in 
the major and through Glu 421 in the minor groove [46]. Each STAT protomer binds 
to a half-site of a palindromic consensus motif termed gamma-interferon activated 
sequence (GAS). STAT1, STAT3, STAT4 and STAT5 bind to half-sites spacing two or 
three base pairs (5′-TTCN2-3GAA-′3), while STAT6 favours a four nucleotide spacer 
within the palindrome [84, 85]. The nucleotides between and around the core 
palindrome impart some level of specificity.
The implication of impaired DNA-binding activity became evident, when STAT1 
mutants were engineered by substituting numerous residues within the DNA-binding 
domain that potentially make contacts with the phosphodiester backbone of the 
DNA. The introduction of positive, negative or neutral charges was intended to 
increase or reduce electrostatic interactions between STAT1 and DNA, respectively. 
A STAT1 mutant termed STAT1 DNAminus, in which negative charges were introduced 
by substituting aspartic acid (Asp) for valine (Val) at position 426 (Val426Asp) and 
threonine at position 427 (Thr427Asp), was normally tyrosine phosphorylated in 
response to IFN-γ but essentially lost its DNA-binding activity [27]. The STAT1 
DNAminus mutant was highly susceptible to inactivation by the nuclear phosphatase 
Tc45 and failed to accumulate in the nucleus. In contrast, the mutant STAT1 DNAplus 
(Thr327Arg; Val426His; Thr427His) was capable of strongly binding to both specific GAS 
sites and nonspecific DNA sequences with nearly equal affinity. This mutant lost its 
discrimination for GAS sites and, due to its hindered dissociation from DNA, resisted 
dephosphorylation, resulting in prolonged nuclear accumulation [27]. These and 
additional experiments indicated that DNA binding determines the accumulation of 
STAT1 in the nucleus. This assumption was corroborated by the finding that high-
affinity DNA binding reduces the dissociation rate of STAT1 dimers from DNA and 
impairs the interdimeric exchange of their protomers in the presence of DNA [57].
In contrast to STAT1 DNAplus, substitution of two glutamic acid residues 
(Glu411Ala; Glu421Lys) generates a double mutant, which maintains the discrimina-
tion between GAS and nonspecific sites. However, STAT1-DNA complexes are stabi-
lised independent of the nucleotide sequence, leading to persistent and enhanced 
tyrosine phosphorylation and prolonged nuclear accumulation [86]. The presence 
of negatively charged residues at these positions is critical for the release of STAT1 
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from DNA. IFN-γ-induced expression of reporter genes and endogenous target 
genes is dramatically reduced in cells expressing STAT1 DNAplus, STAT1 Glu411Ala 
or STAT1 Glu421Lys [27, 86]. In summary, these data revealed the significance 
of sequence-specific DNA binding and fast dissociation from DNA for efficient 
STAT1-mediated gene regulation. An impaired dissociation of STAT1 from genomic 
DNA not only interferes with the continuous search for GAS sites but also prevents 
fast nucleocytoplasmic shuttling and full transcriptional activity of STAT1.
Early studies on the DNA binding of STATs revealed that their binding sites 
can extend over two or more adjacent consensus motifs and that activated STAT1, 
STAT3, STAT4 and STAT5 dimers can interact in homotypic fashion to polymerise on 
such DNA sequences, that is form tetramers or even higher order oligomers [48, 87–
91]. GAS motifs linked in tandem orientation have been identified in various STAT-
driven target genes, including, for example, those encoding IFN-γ [90], interleukin 
2 receptor α (IL-2Rα) [87, 88], perforin [92], cytokine-inducible SH2-containing 
protein (CIS) [93], α2-macroglobulin (α2-M) [91], and glycosylation-dependent cell 
adhesion molecule 1 (GlyCam1) [94]. The synergistic recognition of DNA, generally 
referred to as cooperative DNA binding, is mediated by the conserved N-terminal 
domain of the STAT proteins. It was shown that deletion or mutation of the STAT 
N-terminus abolishes cooperative dimer-dimer interactions [48, 89–91, 95].
Analysis of the crystal structure of the N-domain dimer has indicated an exten-
sive interface involving interactions between hydrophobic residues [96]. Targeted 
mutagenesis has revealed an orthologue residue (Phe 77 in STAT1 and Phe 81 in 
STAT5A/B, respectively) as physiologically most relevant for the oligomerisation 
of STAT proteins [95, 96]. Substitution of alanine for the critical phenylalanine in 
STAT1 does not overtly affect DNA binding on a single GAS site in response to IFN-γ 
but severely impairs tetramerisation [95, 97]. The cooperative binding of STAT1 
dimers strongly increases their DNA-binding affinity [89]. Such interactions do not 
require high-affinity GAS sites linked in tandem orientation. In vitro studies have 
revealed the recruitment of multiple STAT1 dimers to a single GAS site adjacent to 
low-affinity or even GAS-unrelated sequences [95]. Thus, N-domain interactions 
of DNA-bound STAT1 molecules greatly expand the repertoire of potential STAT1-
regulated IFN-γ target genes. An in silico analysis revealed that although single GAS 
sites frequently occur in the mouse genome, GAS sites linked in tandem orienta-
tion are rare and may not be enriched in IFN-γ target genes [97]. Paradoxically, a 
genome-wide transcriptional analysis revealed that STAT1-mediated cooperative 
DNA binding is indispensable for IFN-γ signalling, since the IFN-γ response is 
essentially lost in murine cells expressing the STAT1 F77A mutant [97]. Furthermore, 
cooperativity-deficient STAT1 F77A showed a pervasive promoter recruitment defect 
at GAS-containing IFN-γ-driven but not IFN-α/β-driven genes. It has, therefore, 
been proposed that STAT1 tetramerisation or polymerisation originates from a GAS 
site and then proceeds with loose additional requirements for adjacent sequences 
[97]. Infection experiments have highlighted the physiological relevance of STAT1 
tetramerisation. Listeria monocytogenes infection of STAT1 F77A-expressing mice 
revealed a severe defect in antibacterial immunity. The STAT1 cooperativity-defi-
cient animals succumbed more easily than their wild-type littermates [97].
The crystal structure of the unphosphorylated STAT1 dimer indicates that the 
dimerisation interface is composed of the phenylalanine residue 172 in the coiled-
coil domain of one protomer, which reciprocally is inserted into a pocket in the 
DNA-binding domain of its partner molecule. This pocket is created by the residues 
Q340, L383, G384, T385, H406, L407 and Q408 [52]. Several GOF mutations have 
been identified at this interdimeric interface [98, 99]. Studies on the molecular 
basis of these point mutations underscore the paramount importance of the con-
formational shift for STAT1-driven gene expression [98]. The critical phenylalanine 
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residue 172 is in close proximity (7 Å) to the threonine residue 385 at the surface of 
the partner protomer (Figure 3E). Its substitution impedes the reciprocal interac-
tions between the coiled-coil and DNA-binding domain of the two interacting 
STAT1 molecules, thereby negatively affecting the stability of the antiparallel 
dimer conformation. Shifting the conformational equilibrium towards the parallel 
conformation buries the critical tyrosine residue 701 inside the SH2 domain and, 
thus, prevents access for nuclear phosphatases.
Another interesting phenotype was reported from the targeted mutagenesis of 
the phenylalanine residue 364. The crystal structure indicates that this residue locates 
in the centre of the DNA-binding domain and contributes to the gross structural 
alignment of this domain (Figure 3). The F364A mutant is characterised by tyrosine 
hyper-phosphorylation in response to stimulation of cells with IFN-γ, most likely 
because of its hampered interaction with the Tc45 phosphatase and, in addition, a 
significantly reduced DNA-binding activity. The data suggest that Phe 364 is crucial 
for stabilising the antiparallel dimer and, in addition, for recognising DNA-binding 
sites. When assessed for its ability to induce endogenous STAT1-regulated genes, the 
mutant unexpectedly shows a well-preserved transcriptional activity. Remarkably, it 
appears that a shift in the equilibrium towards the parallel dimer conformation can 
compensate for a critical impairment in high-affinity DNA binding, restoring nearly 
full transcriptional activity at IFN-γ-induced target genes [21].
7. Phenotypes of patients with inborn errors of human STAT1
Regulation of the JAK-STAT signalling pathway is most critical, and dysfunc-
tions in this pathway are associated with various immune disorders and cancer. 
Either the loss of STAT transcriptional activity or uncontrolled constitutive, 
prolonged activity can have devastating effects. Recent progress in the genetic 
dissection of various human infectious diseases has shed light on the inborn errors 
of human STAT1-mediated immunity. In the latest version of the publicly accessible 
section of the Human Gene Mutation Database (HGMD), more than 40 missense/
nonsense mutations in the Stat1 gene have been listed as disease-causing muta-
tions. These include mutations with (i) autosomal recessive (AR) complete STAT1 
deficiency, (ii) AR partial STAT1 deficiency, (iii) autosomal dominant (AD) STAT1 
deficiency and (iv) AD gain-of-function activity. Biallelic and even monoallelic 
loss-of-function (LOF) mutations have been associated with lethal or milder patho-
genesis of intramacrophagic bacterial and viral diseases. In addition, STAT1 LOF 
mutations have been identified in the rare syndrome of Mendelian susceptibility to 
mycobacterial disease (MSMD), which is characterised by infections with weakly 
virulent mycobacteria in otherwise healthy individuals. Patients with immunologi-
cal defects caused by gain-of-function (GOF) mutations suffer from autoimmunity 
and recurrent or persistent infections of nails, skin and mucous membranes with 
the opportunistic yeast pathogen Candida albicans, referred to as chronic mucocu-
taneous candidiasis (CMC) [100–102] (Table 1).
Studying the structural and functional impact of STAT1 missense mutations 
has greatly contributed to our current understanding of cytokine-regulated 
transcriptional activity. To decipher the underlying molecular mechanisms of the 
known STAT1-mediated immunodeficiencies, the pathogenic amino-acid substitu-
tions need to be assigned to the structural changes they induce in the context of 
intra- and intermolecular interactions [112]. When mapped to the crystal structure, 
it becomes evident that the occurrence of disease-causing mutations is unevenly 
distributed among the different STAT1 domains. It appears that the preferential 
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Figure 4. 
Phenotype of clinically relevant STAT1 GOF mutations. (A, B): Characterisation of the STAT1 mutation 
T385A. (A) Localisation of fusion proteins of green-fluorescent protein-tagged STAT1 in reconstituted 
U3A cells expressing recombinant wild-type STAT1 or STAT1 T385A. Exposure to the kinase inhibitor 
staurosporine resulted in the loss of IFN-γ-induced nuclear accumulation of wild-type STAT1, whereas, in 
contrast, the STAT1 point mutant showed a significantly prolonged nuclear residence. (B) Impaired tyrosine 
dephosphorylation of the GOF mutant, as shown by Western blotting. Incubation of protein extracts from 
STAT1-reconstituted U3A cells with the STAT1-specific nuclear phosphatase TC-PTP (Tc45) led to rapid 
dephosphorylation of wild-type STAT1, while the level of tyrosine phosphorylation was prolonged in the T385A 




residue 172 is in close proximity (7 Å) to the threonine residue 385 at the surface of 
the partner protomer (Figure 3E). Its substitution impedes the reciprocal interac-
tions between the coiled-coil and DNA-binding domain of the two interacting 
STAT1 molecules, thereby negatively affecting the stability of the antiparallel 
dimer conformation. Shifting the conformational equilibrium towards the parallel 
conformation buries the critical tyrosine residue 701 inside the SH2 domain and, 
thus, prevents access for nuclear phosphatases.
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full transcriptional activity at IFN-γ-induced target genes [21].
7. Phenotypes of patients with inborn errors of human STAT1
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section of the Human Gene Mutation Database (HGMD), more than 40 missense/
nonsense mutations in the Stat1 gene have been listed as disease-causing muta-
tions. These include mutations with (i) autosomal recessive (AR) complete STAT1 
deficiency, (ii) AR partial STAT1 deficiency, (iii) autosomal dominant (AD) STAT1 
deficiency and (iv) AD gain-of-function activity. Biallelic and even monoallelic 
loss-of-function (LOF) mutations have been associated with lethal or milder patho-
genesis of intramacrophagic bacterial and viral diseases. In addition, STAT1 LOF 
mutations have been identified in the rare syndrome of Mendelian susceptibility to 
mycobacterial disease (MSMD), which is characterised by infections with weakly 
virulent mycobacteria in otherwise healthy individuals. Patients with immunologi-
cal defects caused by gain-of-function (GOF) mutations suffer from autoimmunity 
and recurrent or persistent infections of nails, skin and mucous membranes with 
the opportunistic yeast pathogen Candida albicans, referred to as chronic mucocu-
taneous candidiasis (CMC) [100–102] (Table 1).
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transcriptional activity. To decipher the underlying molecular mechanisms of the 
known STAT1-mediated immunodeficiencies, the pathogenic amino-acid substitu-
tions need to be assigned to the structural changes they induce in the context of 
intra- and intermolecular interactions [112]. When mapped to the crystal structure, 
it becomes evident that the occurrence of disease-causing mutations is unevenly 
distributed among the different STAT1 domains. It appears that the preferential 
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localisation of LOF mutations is less well defined as compared to the more restricted 
localisation of GOF mutations. The critical LOF substitutions are widely scattered 
in the coiled-coil, DNA-binding and SH2 domains, as well as in the tail segment. In 
contrast, the GOF mutations identified so far are exclusively clustered in the coiled-
coil and DNA-binding domains. The crystal structure of tyrosine-phosphorylated, 
DNA-bound STAT1 shows that the coiled-coil domain prominently protrudes 
outward [46]. Therefore, it was initially postulated that the coiled-coil domain may 
function as a docking site for transcription factors and coactivators to cooperatively 
facilitate STAT1-dependent gene transcription and that the GOF mutations in this 
domain may enhance these interactions. Typically, pathogenic GOF mutations clus-
ter in structural areas of the STAT1 protein, which markedly affect the regulation of 
its transcriptional activity. As described above, the conformational rearrangement 
from the parallel to the antiparallel dimer conformation is a prerequisite for the 
inactivation of STAT1 and requires, as a conditio sine qua non, the dissociation into 
monomers. Monomeric STAT1 spontaneously reassociates into either the parallel 
or antiparallel conformation. In the parallel alignment, STAT1 regains its DNA-
binding activity with the chance of participating in another round of transcrip-
tional initiation of target genes. It appears that the antiparallel conformation of the 
STAT1 dimer is the substrate for the highly active Tc45 phosphatase, which rapidly 
dephosphorylates the critical tyrosine residue 701 followed by nuclear export of the 
now transcriptionally inactive molecule. As described above, the formation of the 
antiparallel dimer is facilitated by reciprocal interactions between the coiled-coil 
and the DNA-binding domain and, thus, it is not surprising that mutations in this 
critical area affect the stability of this complex.
Experimental data revealed that the two point mutants STAT1 F172W and T385A 
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gain-of-function; LOF, loss-of-function; ND, amino-terminal domain; SH2, src-homology-2 domain; TS, tail 
segment.
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prolonged nuclear accumulation in cells exposed to IFN-γ (Figure 4A, B) [113]. 
The resulting phenotype is associated with enhanced tyrosine phosphorylation in 
response to various cytokine stimuli, including IFN-α, IFN-γ, IL-6, IL-21 and IL-27 
[23, 110, 113–115]. The functional characterisation of the disease-causing interface 
mutations has demonstrated sequence-specific requirements for differential gene 
expression of endogenous IFN-γ target genes. The expression of genes with a clas-
sical GAS consensus-binding motif, including interferon-regulatory factor 1 (irf1), 
guanylate-binding protein 1 (gbp1) and monokine induced by interferon gamma 1  
(mig1), is virtually unaffected by these mutations. In contrast, transcription of 
genes, such as CXC motif chemokine 10 (cxcl10) and monocyte chemotactic protein 1 
(mcp1/cxcl9) is greatly increased, which have a “one-and-a-half-GAS” element in 
their promoters, that is, half of the palindromic motif adjacent to the GAS site 
[113]. The superiority of the STAT1 mutants as transcriptional activators appears 
to directly reflect their enhanced binding as tetramers to these “one-and-a-half-
GAS” sequences. The increased DNA binding for these mutants contributes to 
their pathologically elevated level of tyrosine phosphorylation. However, numer-
ous disease-associated GOF mutations are not directly located at the surface of the 
interdimeric interface but rather disturb the gross architecture of this interface 
(Figure 3).
A prominent and well-studied example is the GOF mutation resulting from the 
exchange of the arginine 274 residue in the coiled-coil domain (Figure 4C). A change 
in the local structure induced by this substitution may impair the stability of the 
antiparallel dimer. Consistently, a genome-wide expression profile indicated that the 
pathogenic R274Q mutation increased the IFN-γ-induced transcriptional activity of 
STAT1 but overall retained its sequence specificity [98]. In other words, the mutation 
increases the expression rate of STAT1 target genes but does not dramatically change 
its repertoire. However, the molecular mechanisms of this GOF mutation are not fully 
understood. In particular, it is unclear whether this missense mutation affects the 
kinetics of JAK-induced phosphorylation or, alternatively, its dephosphorylation rate.
8. Concluding remarks
Activation at the IFN receptor and sequence-specific, cooperative DNA binding 
are key features of STAT1 signal transduction. Cytoplasmic and nuclear activities 
are functionally coupled by repetitive cycles of STAT1 phosphorylation and dephos-
phorylation. This highly dynamic activation-inactivation circuit is controlled by a 
shift between the parallel and antiparallel dimer conformers. Missense mutations in 
either the coiled-coil or DNA-binding domain destabilising the antiparallel dimer 
critically interfere with the equilibrium between the two conformers. Genetic varia-
tions affecting this intradimeric interface result in enhanced cytokine-induced gene 
expression and cause severe immunodeficiencies in heterozygous mutation carriers.
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prolonged nuclear accumulation in cells exposed to IFN-γ (Figure 4A, B) [113]. 
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response to various cytokine stimuli, including IFN-α, IFN-γ, IL-6, IL-21 and IL-27 
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expression of endogenous IFN-γ target genes. The expression of genes with a clas-
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pathogenic R274Q mutation increased the IFN-γ-induced transcriptional activity of 
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increases the expression rate of STAT1 target genes but does not dramatically change 
its repertoire. However, the molecular mechanisms of this GOF mutation are not fully 
understood. In particular, it is unclear whether this missense mutation affects the 
kinetics of JAK-induced phosphorylation or, alternatively, its dephosphorylation rate.
8. Concluding remarks
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are key features of STAT1 signal transduction. Cytoplasmic and nuclear activities 
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phorylation. This highly dynamic activation-inactivation circuit is controlled by a 
shift between the parallel and antiparallel dimer conformers. Missense mutations in 
either the coiled-coil or DNA-binding domain destabilising the antiparallel dimer 
critically interfere with the equilibrium between the two conformers. Genetic varia-
tions affecting this intradimeric interface result in enhanced cytokine-induced gene 
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Abstract
E2F and DP family proteins are evolutionally conserved transcription factors 
among higher eukaryotes. E2F and DP proteins typically form a heterodimeric 
complex, which controls cell proliferation by regulating expression of growth-
related genes. In addition, E2F family proteins have roles in various cellular events 
that require the expression of context-specific genes. E2F proteins use distinct 
mechanisms to regulate context-specific genes in different circumstances. The 
primary goal of this chapter is to compare three distinct mechanisms of mam-
malian E2F-mediated transcriptional regulation that control cell proliferation, 
endoreplication and apoptosis. Briefly, E2F7 and E2F8 control endoreplication by 
suppressing the expression of their target genes. They do not require DP or pRb. In 
control of apoptosis, E2F1 regulates the expression of the tumor suppressor gene 
Arf by binding to a non-canonical E2F binding site, within the Arf promoter, in a 
DP-independent manner. Furthermore, we examine the functions of E2F and DP in 
Drosophila melanogaster (fruit fly) to identify those mechanisms of E2F-mediated 
transcriptional regulation that have been evolutionarily conserved. The detailed 
mechanisms of how E2F protein regulates the expression of context-specific target 
genes will be instrumental in understanding how a single family of transcription 
factor regulates diverse pleiotropic cellular processes in an organism.
Keywords: E2F, DP, pRb, Arf, p53, cell cycle, endoreplication, apoptosis
1. Introduction
The temporal control of gene expression is essential to the execution of cellular 
events such as proliferation, growth, self-renewal, differentiation and death. For 
example, a proliferating cell performs the sequential processes of the cell cycle by 
the orderly expression of genes involved in DNA replication, DNA repair, mitosis 
and cytokinesis [1, 2]. During the cell cycle, E2 promoter binding factor (E2F) and 
DRTF1-polypeptide (DP) form a heterodimeric complex E2F/DP, which functions 
with retinoblastoma protein (pRb) to regulate the timing of expression of growth-
related genes at the level of transcription [1–5]. In quiescent cells, the E2F/DP 
complexes interact with pRb family proteins to prevent cell cycle re-entry by actively 
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1. Introduction
The temporal control of gene expression is essential to the execution of cellular 
events such as proliferation, growth, self-renewal, differentiation and death. For 
example, a proliferating cell performs the sequential processes of the cell cycle by 
the orderly expression of genes involved in DNA replication, DNA repair, mitosis 
and cytokinesis [1, 2]. During the cell cycle, E2 promoter binding factor (E2F) and 
DRTF1-polypeptide (DP) form a heterodimeric complex E2F/DP, which functions 
with retinoblastoma protein (pRb) to regulate the timing of expression of growth-
related genes at the level of transcription [1–5]. In quiescent cells, the E2F/DP 
complexes interact with pRb family proteins to prevent cell cycle re-entry by actively 
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repressing the expression of growth-related genes (Figure 1A and B). Mitogenic 
signals promote the assembly and activation of the Cyclin D/cyclin-dependent 
kinase (cdk) 4 complex in the cell nucleus. Phosphorylation of pRb family proteins 
by the Cyclin D-cdk4 complex results in their dissociation from the E2F/DP complex 
(Figure 1A), and consequently growth-related genes are de-repressed. The free E2F/
DP complexes also promote transcription of their target genes (Figure 1A and B). 
Primary E2F target genes in the cell cycle encode DNA-replication factors. In addi-
tion, the E2F/DP complex induces the expression of cyclins (E, A, and B) and genes 
involved in DNA repair, mitosis and cytokinesis. Thus, the pRb/E2F/DP pathway 
controls not only the G1/S transition, but also influences other processes of the cell 
cycle. Once the level of mitogen signals is reduced, cdk activity is down-regulated, 
under-phosphorylated pRb family proteins accumulate, E2F activity is repressed, 
and cells exit from the cell cycle.
Genome wide gene expression profiles and analysis of the function of individual 
E2F family proteins have revealed that E2F family members have roles in various 
cellular processes including endoreplication [6], cell death [7], autophagy [8] and 
differentiation [9]. Since it is unlikely that E2F simultaneously induces genes involved 
in these distinct, often mutually exclusive cellular processes, cells must have multiple 
mechanisms, by which specific E2F target genes are expressed to function in line with 
intracellular circumstances. Indeed, the mechanism of E2F1 regulation of tumor sup-
pressor genes, Alternative reading frame of cdkn2a (Arf ), p27 and p73 is distinct from 
that of growth-related genes [10–12]. Surprisingly, the requirement for DP is different 
between E2F1 regulation of Arf and growth-related genes such as cell division cycle 6 
(cdc6), implying that DP protein is not involved in all E2F-mediated transcriptional 
regulation [13]. In this chapter, we describe mechanisms of E2F-mediated transcrip-
tional regulation in three different cellular functions, cell proliferation, endoreplica-
tion and apoptosis, and discuss the requirement for DP in these processes. In addition, 
we compare and contrast these mechanisms in mammals and flies, to identify those 
that have been conserved or emerged during the process of evolution.
Figure 1. 
The E2F/DP complex controls cell cycle progression with pRB. (A) Schematic view of the pRb/E2F/DP 
pathway. Solid line indicates the function of pRb/E2F/DP complex to repress the expression of growth-related 
E2F-target genes in quiescence. Dashed arrows indicate the signal cascade following activation by mitogenic 
signals. pRb-P indicates phosphorylated pRb. (B) Regulation of growth-related E2F target genes by the pRB/
E2F/DP complex during the cell cycle. The pRb/E2F/DP complex actively represses the transcription of growth-
related E2F target genes in quiescence, while free activator E2F/DP complex promotes transcription of the 
target genes when pRb family proteins are phosphorylated by G1-cyclin/cdk.
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2. Structures of mammalian and fly E2F and DP family members
The human and mouse genomes contain eight E2F family genes and three DP 
family genes (Figure 2) [3]. E2F family proteins can be distinguished as “activa-
tor” or “repressor” by their functions in transcription, or “typical” or “atypical” 
based on their structure. E2F1–5 genes encode proteins composed of a winged-
helix DNA-binding domain (DBD), Leucine zipper (LZ) domain, Marked-box 
(MB) domain and transactivation domain (TAD) that includes pRb-binding 
motif (Figure 2). E2F6 protein lacks the TAD and pRb-binding motif (Figure 2). 
E2F1–3a are categorized as activator E2Fs because they are essential to activate 
transcription of target genes in cell culture [3]. E2F3b-5 are designated repres-
sor E2Fs since their main function is to suppress the expression of target genes 
by interacting with pRb family proteins in resting states [14–16]. E2F6 is also a 
repressor E2F, but functions without interacting pRb family proteins [17–19]. 
E2F1–6 proteins interact with one of the DP proteins through LZ and MB 
domains (dimerization domain: DD). All DP family members possess a DBD and 
DD [3]. In addition, the C-terminus of DP1 can interact with TFIIH, suggesting 
that DP1 directly contributes to activation of target gene transcription [20]. DP1 
and DP2 support the transcriptional activation of E2F target genes while DP3 
functions to inhibit E2F-dependent transcription [21, 22]. The E2F/DP complex 
typically recognizes specific DNA sequences TTTC/GG/CCGC/G (hereafter referred 
to as “canonical E2F binding site” in this chapter) [23]. E2F1 is also able to 
Figure 2. 
E2F and DP family members in human, mouse and fly. E2F families can be divided into two groups by 
functional or structural properties. Activator E2Fs are required to induce expression of growth-related E2F 
target genes at G1/S phase transition. E2F3a-5 are expressed in quiescence (G0) and G1 phase to repress target 
gene transcription by pRb-dependent mechanisms. E2F6–8 have the ability to repress target gene transcription 
by pRb-independent mechanisms. Typical E2Fs possess DBD, LZ, MB and TAD, while atypical E2Fs possess 
two DBD without a TAD. DP family proteins share DBD and LZ. TAD is found in mammalian DP1.
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repressing the expression of growth-related genes (Figure 1A and B). Mitogenic 
signals promote the assembly and activation of the Cyclin D/cyclin-dependent 
kinase (cdk) 4 complex in the cell nucleus. Phosphorylation of pRb family proteins 
by the Cyclin D-cdk4 complex results in their dissociation from the E2F/DP complex 
(Figure 1A), and consequently growth-related genes are de-repressed. The free E2F/
DP complexes also promote transcription of their target genes (Figure 1A and B). 
Primary E2F target genes in the cell cycle encode DNA-replication factors. In addi-
tion, the E2F/DP complex induces the expression of cyclins (E, A, and B) and genes 
involved in DNA repair, mitosis and cytokinesis. Thus, the pRb/E2F/DP pathway 
controls not only the G1/S transition, but also influences other processes of the cell 
cycle. Once the level of mitogen signals is reduced, cdk activity is down-regulated, 
under-phosphorylated pRb family proteins accumulate, E2F activity is repressed, 
and cells exit from the cell cycle.
Genome wide gene expression profiles and analysis of the function of individual 
E2F family proteins have revealed that E2F family members have roles in various 
cellular processes including endoreplication [6], cell death [7], autophagy [8] and 
differentiation [9]. Since it is unlikely that E2F simultaneously induces genes involved 
in these distinct, often mutually exclusive cellular processes, cells must have multiple 
mechanisms, by which specific E2F target genes are expressed to function in line with 
intracellular circumstances. Indeed, the mechanism of E2F1 regulation of tumor sup-
pressor genes, Alternative reading frame of cdkn2a (Arf ), p27 and p73 is distinct from 
that of growth-related genes [10–12]. Surprisingly, the requirement for DP is different 
between E2F1 regulation of Arf and growth-related genes such as cell division cycle 6 
(cdc6), implying that DP protein is not involved in all E2F-mediated transcriptional 
regulation [13]. In this chapter, we describe mechanisms of E2F-mediated transcrip-
tional regulation in three different cellular functions, cell proliferation, endoreplica-
tion and apoptosis, and discuss the requirement for DP in these processes. In addition, 
we compare and contrast these mechanisms in mammals and flies, to identify those 
that have been conserved or emerged during the process of evolution.
Figure 1. 
The E2F/DP complex controls cell cycle progression with pRB. (A) Schematic view of the pRb/E2F/DP 
pathway. Solid line indicates the function of pRb/E2F/DP complex to repress the expression of growth-related 
E2F-target genes in quiescence. Dashed arrows indicate the signal cascade following activation by mitogenic 
signals. pRb-P indicates phosphorylated pRb. (B) Regulation of growth-related E2F target genes by the pRB/
E2F/DP complex during the cell cycle. The pRb/E2F/DP complex actively represses the transcription of growth-
related E2F target genes in quiescence, while free activator E2F/DP complex promotes transcription of the 
target genes when pRb family proteins are phosphorylated by G1-cyclin/cdk.
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E2F1–3a are categorized as activator E2Fs because they are essential to activate 
transcription of target genes in cell culture [3]. E2F3b-5 are designated repres-
sor E2Fs since their main function is to suppress the expression of target genes 
by interacting with pRb family proteins in resting states [14–16]. E2F6 is also a 
repressor E2F, but functions without interacting pRb family proteins [17–19]. 
E2F1–6 proteins interact with one of the DP proteins through LZ and MB 
domains (dimerization domain: DD). All DP family members possess a DBD and 
DD [3]. In addition, the C-terminus of DP1 can interact with TFIIH, suggesting 
that DP1 directly contributes to activation of target gene transcription [20]. DP1 
and DP2 support the transcriptional activation of E2F target genes while DP3 
functions to inhibit E2F-dependent transcription [21, 22]. The E2F/DP complex 
typically recognizes specific DNA sequences TTTC/GG/CCGC/G (hereafter referred 
to as “canonical E2F binding site” in this chapter) [23]. E2F1 is also able to 
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functional or structural properties. Activator E2Fs are required to induce expression of growth-related E2F 
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bind to a non-canonical E2F binding site called E2F-responsive element of Arf 
(EREA), comprised of the sequence CGCGCGCGCGCCTCC [10].
After completion of the human and mouse genome sequencing projects, 
searches for homologous sequences to the E2F-DBD identified atypical E2F family 
members, E2F7 and E2F8 that are structurally distinct from E2F1 to 6 (Figure 2) 
[24–29]. E2F7 and 8 contain two DBDs but lack a transactivation domain. These 
atypical E2Fs recognize canonical E2F binding sites in a DP-independent manner 
and function to repress transcription of E2F target genes by a pRb-independent 
mechanism.
The fly genome contains two e2f genes and a single dp gene [3, 4, 30]. de2f1 
encodes two isoforms, which function as transcriptional activators, while dE2f2 acts 
as a repressor in transcription (Figure 2) [31, 32]. Because all other higher eukary-
otes also possess functional homolog of activator E2F, repressor E2F and DP, the 
mechanism of transcriptional control by the E2F/DP complex has been evolution-
ally conserved [33]. Atypical E2Fs are shared in several model organisms including 
mammals, worm and plant, but not in fly (Figure 2) [33]. DP-independent tran-
scriptional regulation by atypical E2Fs seems to have been emerged and been lost 
during the process of evolution.
3. The role of the E2F/DP complex in cell proliferation
3.1 DP is essential in transcriptional regulation of growth-related E2F target 
genes in cultured cells
The concept of the pRb/E2F/DP pathway is based primarily on evidence 
obtained using rodent fibroblasts in culture [1–5]. The advantage of this system 
is the ease of manipulating the proliferative capacity of cells without losing cell 
viability by the absence or presence of fetal bovine serum in the culture medium 
[34, 35]. Fibroblasts continuously proliferate in culture medium that contains 
abundant serum. Withdrawing serum from the media causes cells to exit from the 
cell cycle, while re-introduction of serum leads to re-entry into the cell cycle. Thus, 
this system enables control of endogenous E2F activity by manipulating the amount 
of serum in culture media. In addition, using expression vectors and recombinant 
adenovirus containing various E2F genes, we can examine the specific activity of 
individual E2F proteins in quiescent fibroblast without other confounding prolif-
erating signals [2]. The functional analysis of individual E2F proteins in quiescent 
fibroblasts revealed that activator E2Fs are sufficient to promote the G1/S transition 
in the cell cycle [34, 35]. Conversely, loss of activator E2Fs causes cell cycle arrest at 
G1 phase [36]. Accordingly, DP1 is required for G1/S transition and cell prolifera-
tion in human fibroblasts [13]. These observations indicate that the activator E2F/
DP complexes promote and regulate the G1/S transition in cultured cells. However, 
subsequent studies revealed that the cell cycle arrest caused by concomitant loss of 
activator E2Fs in cultured fibroblasts is mediated through the p53-p21 axis, which 
reduces cdk activity [37]. Inactivation of p53 restores the proliferative ability of 
E2f1–3 triple mutant fibroblasts [38]. These results suggest that cells have permis-
sive factor(s), which promote G1/S transition in the absence of activator E2Fs, and 
raise the question of how activator E2Fs suppress p53 activity in proliferating cells. 
A strong candidate of E2F target genes that induce activation of p53 in this context 
was Arf, since permanent loss of E2f3 induces Arf expression [38, 39]. However, 
acute inactivation of E2F activators does not increase Arf expression and activa-
tion of p53 does not require Arf in E2f1–3 triple mutant fibroblasts [38]. Therefore, 
induction of Arf gene expression by loss of E2f3 is presumably an indirect effect 
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and activator E2Fs suppress activation of p53 by Arf-independent mechanisms 
in fibroblasts. Elucidating the mechanisms, by which activator E2Fs suppress p53 
activity in proliferating cells, will provide deeper understanding of how activator 
E2Fs regulate cell proliferation.
Cell culture systems and in vitro biochemical experiments have also revealed 
molecular mechanisms underlying transcriptional regulation of target genes by 
the E2F/DP complex [1, 2, 5]. Expression levels of growth-related E2F target genes 
are very low in quiescent fibroblasts, while serum stimulation increases the expres-
sion of these genes concomitant with phosphorylation of pRb family proteins 
by G1-cyclin/cdks [1–5]. Indeed, loss of all Rb family genes increases the level of 
growth-related E2F target gene expression in quiescent mouse fibroblasts [40]. The 
concept that pRb/E2F/DP complex actively represses the transcription of growth-
related E2F target genes in quiescence was conceived based on results from reporter 
assays, in which the promoter region of an E2F target gene is isolated and fused 
upstream of a reporter gene such as chloramphenicol acetyltransferase or luciferase 
to monitor promoter activity [34, 41]. Analysis of such reporter activity during 
the cell cycle revealed that the wild-type promoter recapitulates endogenous gene 
expression patterns throughout the cell cycle, while mutations in canonical E2F 
binding sites de-represses the promoter activity in quiescence and does not allow 
further up-regulation at the G1/S transition (Figure 3). E2F4 and p130 occupied 
canonical E2F binding sites on promoters of growth-related E2F target genes in 
quiescence [14, 16]. DP1 is required for E2F4 binding on the promoter of cdc6 in 
quiescent human fibroblasts and for repression of the cdc6 promoter activity [13] 
(Komori & Ohtani unpublished data). pRb family proteins repress E2F target 
promoter activity by recruiting histone modifier proteins and chromatin remodel-
ing complexes [42–47]. Thus, the repressor E2F/DP complex acts as a platform on 
the target promoters to recruit pRb family proteins, which induce a dynamic change 
of chromatin structure, robustly shutting down the transcription of growth-related 
E2F target genes (Figure 1B).
Activator E2Fs induce stronger activation of E2F target gene transcription 
compared to repressor E2Fs in reporter assays. Co-overexpression of DPs induces 
further activation of reporter transcription while knockdown of DP1 reduces pro-
moter activity induced by activator E2Fs [13, 48, 49]. Thus, DP is essential for both 
active repression and activation of growth-related E2F target gene transcription 
Figure 3. 
The promoter activity of growth-related E2F target genes during the cell cycle. Solid line indicates the activity 
of wild-type promoter of growth-related E2F target genes. Dashed line indicates the activity of canonical E2F 
binding site mutant promoter of growth-related E2F target genes. The difference in promoter activity between 
wild-type and E2F binding site mutant is due to pRB/E2F/DP complex-dependent repression. Activator E2Fs 
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(Figure 1B). The main role of DP in the regulation of growth-related E2F target 
gene expression is in DNA binding of the E2F/DP complex [3, 20]. A monomer of 
E2F or DP is able to bind to DNA in vitro, whereas the heterodimer complex shows 
much stronger DNA binding affinity [48, 49]. Structural analysis of the complex of 
E2F4/DP2 bound to a canonical E2F binding site revealed that the E2F/DP complex 
holds DNA by DBDs of both E2F and DP [50]. Thus, DP protein ensures a stable 
binding of the E2F/DP complex to precisely control expression of growth-related 
E2F target genes during the cell cycle.
3.2 The role of the E2F/DP complex in mouse development
In order to form functional tissues and organs, stem cells and progenitor cells 
continuously proliferate to generate progeny cells, which must exit from the cell 
cycle at the onset of commitment to a differentiated state [51]. Because loss of all 
activator E2Fs or loss of DP1 induces cell cycle arrest of cells in culture [13, 36, 52], 
E2f1–3 triple mutant was expected to show a premature exhaustion of cell prolifera-
tion during development. However, the E2f1–3 triple mutant mouse embryo grows 
to mid-gestation stage without severe defects of cell proliferation [53, 54]. In the 
absence of activator E2Fs, the Myc family transcription factors compensate for their 
function to promote the G1/S transition [54, 55]. n-Myc can functionally substitute 
for activator E2Fs in retinal progenitors, while c-Myc complements activator E2Fs 
in intestinal stem cells. E2f1–3 triple mutant embryos also exhibit an apoptotic 
phenotype in multiple tissues, in which activation of p53 is observed. This suggests 
that activator E2Fs suppress the activation of p53 during development in vivo, in 
addition to cells in culture. E2f1–3 triple knock out analysis revealed another aspect 
of the function of activator E2Fs [55]. The expression of growth-related E2F target 
genes is increased by inactivation of E2f1–3 in differentiated cells while loss of 
E2F1–3 reduces the expression of growth-related E2F target genes in proliferating 
progenitor cells, suggesting that E2F1–3 contribute to repress target gene expression 
in differentiated cells. However, loss of E2F1–3 does not induce differentiated cells 
to re-enter into the cell cycle, implying that, in addition to de-repression of growth-
related E2F target genes, other factors are required to cause re-entry of terminally 
differentiated cells into the cell cycle.
Removing all E2f genes from a single mouse is technically impossible at this 
stage. The DP family has three members and DP1 is highly expressed in many 
tissues. Thus, it is anticipated that loss of DP1 would mimic the phenotype expected 
due to elimination of all E2F/DP complexes in the mouse. DP1 mutant mice die in 
utero due to defects in placenta development, while their somatic cells proliferate 
without severe defects [56, 57]. There is a possibility that other DP family proteins 
complement the function of DP1 in DP1 mutant animals. However, the levels of 
DP2 expression are very low in the wild-type and its expression is not significantly 
changed in DP1 mutant embryos. The expression of DP3 has not been investigated 
in DP1 mutant mice. However, since DP3 inhibits activation of growth-related 
target genes by E2F1 in cultured cells [21, 22], it is not likely that DP3 compensates 
for DP1 function. In conclusion, the E2F/DP complex function is required for 
normal development, but the viability seems to be determined by functions that are 
independent from cell cycle control.
3.3 The role of DP in fly development
Mammalian genomes contain several E2F and DP family members, and their 
functional relationships are very complicated. Because the fly genome contains 
two E2Fs, only one DP and no atypical E2Fs, the combinatorial interactions and 
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possibility of compensation by other family members are more limited [4, 33]. In 
drosophila, loss of de2f1 reduces cell proliferation during development [58]. The 
decline in cell proliferation induced by loss of de2f1 is restored by removing de2f2 
gene function, indicating that dE2f1 and dE2f2 have opposite functions in control of 
cell proliferation [31, 32]. dDP mutant larvae phenocopy the de2f1 and de2f2 double 
mutant with respect to cell proliferation and lethality at the late pupal stage [31, 32]. 
The viability of the dDP mutant fly is rescued by restoring the defects in muscle 
development and/or fat body cell growth [59, 60], implying that the lethality is due 
to non-cell cycle function of dDP. These indicate that the E2F/DP complexes are not 
necessary for cell proliferation during fly development. The possibility that dMyc 
may compensate for the function of the dE2f/dDP complex in cell proliferation has 
yet to be examined.
4. The role of atypical E2Fs in endoreplication
4.1 Atypical E2Fs inhibit cell cycle progression in cultured cell
E2F7 and E2F8 are atypical E2F proteins, which are composed of two DBDs 
lacking a transactivation domain or pRb binding motif (Figure 2) [3, 24–29, 33]. 
They do not interact with DP, and thus atypical E2Fs function independently of DP 
protein. Since overexpression of atypical E2Fs represses the promoter activity of 
growth-related E2F target genes, they are designated repressor E2Fs. They function 
via a pRb-independent mechanism. E2F7 recruits the transcriptional co-repressor 
CtBP to repress the activity of its target promoter in fibroblasts [61]. Details of 
molecular mechanisms of how atypical E2Fs regulate E2F target genes have been 
controversial. DBD1 of E2F7 is similar to the DBD of the E2F family, while DBD2 
of E2F7 is homologous to that of the DP family. Both DBDs are necessary for the 
DNA binding ability of atypical E2Fs. Crystal structure analysis revealed that DBD1 
and DBD2 bind to a typical E2F binding site in a manner similar to the E2F4/DP2 
heterodimeric complex [62]. This suggests the possibility that atypical E2Fs are 
able to function as a monomer (Figure 4A). However, they form a homodimer or 
a heterodimer of E2F7 and E2F8 in cells (Figure 4A) [24–29]. How this dimeric 
complex of atypical E2Fs binds to DNA remains to be addressed. In addition, it is 
reported that E2F7 inhibits the function of E2F1 by direct interaction (Figure 4A) 
[61]. How then does an E2F1/E2F7 heterodimer bind to DNA and how does E2F7 
dominate E2F1 activity on their target promoter? Overexpression of atypical E2Fs 
inhibits proliferation of fibroblasts in culture [24–29]. Expression of atypical E2Fs 
is upregulated in G1/S transition of fibroblasts because their expression is under the 
control of typical E2Fs. These suggest that atypical E2Fs may function as a negative 
feedback loop to antagonize the function of activator E2Fs in S-phase of the cell 
cycle. However, cells can proliferate in the presence of atypical E2Fs. If they are 
dispensable in the control of cell proliferation, what is the role of atypical E2Fs in 
the physiological setting?
4.2 Atypical E2Fs control endoreplication during mouse development
Mouse atypical E2Fs play crucial roles in endoreplication of placental tropho-
blast giant cells (TGCs) and liver hepatocytes [3, 33, 63]. While the archetypal cell 
cycle proceeds to G2 and M phases after completing DNA replication, endoreplica-
tion is a variant cell cycle, which repeats the cycle of G1 and S phase in the absence 
of intervening mitoses (Figure 4B) [64]. Consequently, endoreplication produces 
mononucleated polyploid cells. Since endoreplication does not permit cells to enter 
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(Figure 1B). The main role of DP in the regulation of growth-related E2F target 
gene expression is in DNA binding of the E2F/DP complex [3, 20]. A monomer of 
E2F or DP is able to bind to DNA in vitro, whereas the heterodimer complex shows 
much stronger DNA binding affinity [48, 49]. Structural analysis of the complex of 
E2F4/DP2 bound to a canonical E2F binding site revealed that the E2F/DP complex 
holds DNA by DBDs of both E2F and DP [50]. Thus, DP protein ensures a stable 
binding of the E2F/DP complex to precisely control expression of growth-related 
E2F target genes during the cell cycle.
3.2 The role of the E2F/DP complex in mouse development
In order to form functional tissues and organs, stem cells and progenitor cells 
continuously proliferate to generate progeny cells, which must exit from the cell 
cycle at the onset of commitment to a differentiated state [51]. Because loss of all 
activator E2Fs or loss of DP1 induces cell cycle arrest of cells in culture [13, 36, 52], 
E2f1–3 triple mutant was expected to show a premature exhaustion of cell prolifera-
tion during development. However, the E2f1–3 triple mutant mouse embryo grows 
to mid-gestation stage without severe defects of cell proliferation [53, 54]. In the 
absence of activator E2Fs, the Myc family transcription factors compensate for their 
function to promote the G1/S transition [54, 55]. n-Myc can functionally substitute 
for activator E2Fs in retinal progenitors, while c-Myc complements activator E2Fs 
in intestinal stem cells. E2f1–3 triple mutant embryos also exhibit an apoptotic 
phenotype in multiple tissues, in which activation of p53 is observed. This suggests 
that activator E2Fs suppress the activation of p53 during development in vivo, in 
addition to cells in culture. E2f1–3 triple knock out analysis revealed another aspect 
of the function of activator E2Fs [55]. The expression of growth-related E2F target 
genes is increased by inactivation of E2f1–3 in differentiated cells while loss of 
E2F1–3 reduces the expression of growth-related E2F target genes in proliferating 
progenitor cells, suggesting that E2F1–3 contribute to repress target gene expression 
in differentiated cells. However, loss of E2F1–3 does not induce differentiated cells 
to re-enter into the cell cycle, implying that, in addition to de-repression of growth-
related E2F target genes, other factors are required to cause re-entry of terminally 
differentiated cells into the cell cycle.
Removing all E2f genes from a single mouse is technically impossible at this 
stage. The DP family has three members and DP1 is highly expressed in many 
tissues. Thus, it is anticipated that loss of DP1 would mimic the phenotype expected 
due to elimination of all E2F/DP complexes in the mouse. DP1 mutant mice die in 
utero due to defects in placenta development, while their somatic cells proliferate 
without severe defects [56, 57]. There is a possibility that other DP family proteins 
complement the function of DP1 in DP1 mutant animals. However, the levels of 
DP2 expression are very low in the wild-type and its expression is not significantly 
changed in DP1 mutant embryos. The expression of DP3 has not been investigated 
in DP1 mutant mice. However, since DP3 inhibits activation of growth-related 
target genes by E2F1 in cultured cells [21, 22], it is not likely that DP3 compensates 
for DP1 function. In conclusion, the E2F/DP complex function is required for 
normal development, but the viability seems to be determined by functions that are 
independent from cell cycle control.
3.3 The role of DP in fly development
Mammalian genomes contain several E2F and DP family members, and their 
functional relationships are very complicated. Because the fly genome contains 
two E2Fs, only one DP and no atypical E2Fs, the combinatorial interactions and 
55
Distinct E2F-Mediated Transcriptional Mechanisms in Cell Proliferation, Endoreplication…
DOI: http://dx.doi.org/10.5772/intechopen.82448
possibility of compensation by other family members are more limited [4, 33]. In 
drosophila, loss of de2f1 reduces cell proliferation during development [58]. The 
decline in cell proliferation induced by loss of de2f1 is restored by removing de2f2 
gene function, indicating that dE2f1 and dE2f2 have opposite functions in control of 
cell proliferation [31, 32]. dDP mutant larvae phenocopy the de2f1 and de2f2 double 
mutant with respect to cell proliferation and lethality at the late pupal stage [31, 32]. 
The viability of the dDP mutant fly is rescued by restoring the defects in muscle 
development and/or fat body cell growth [59, 60], implying that the lethality is due 
to non-cell cycle function of dDP. These indicate that the E2F/DP complexes are not 
necessary for cell proliferation during fly development. The possibility that dMyc 
may compensate for the function of the dE2f/dDP complex in cell proliferation has 
yet to be examined.
4. The role of atypical E2Fs in endoreplication
4.1 Atypical E2Fs inhibit cell cycle progression in cultured cell
E2F7 and E2F8 are atypical E2F proteins, which are composed of two DBDs 
lacking a transactivation domain or pRb binding motif (Figure 2) [3, 24–29, 33]. 
They do not interact with DP, and thus atypical E2Fs function independently of DP 
protein. Since overexpression of atypical E2Fs represses the promoter activity of 
growth-related E2F target genes, they are designated repressor E2Fs. They function 
via a pRb-independent mechanism. E2F7 recruits the transcriptional co-repressor 
CtBP to repress the activity of its target promoter in fibroblasts [61]. Details of 
molecular mechanisms of how atypical E2Fs regulate E2F target genes have been 
controversial. DBD1 of E2F7 is similar to the DBD of the E2F family, while DBD2 
of E2F7 is homologous to that of the DP family. Both DBDs are necessary for the 
DNA binding ability of atypical E2Fs. Crystal structure analysis revealed that DBD1 
and DBD2 bind to a typical E2F binding site in a manner similar to the E2F4/DP2 
heterodimeric complex [62]. This suggests the possibility that atypical E2Fs are 
able to function as a monomer (Figure 4A). However, they form a homodimer or 
a heterodimer of E2F7 and E2F8 in cells (Figure 4A) [24–29]. How this dimeric 
complex of atypical E2Fs binds to DNA remains to be addressed. In addition, it is 
reported that E2F7 inhibits the function of E2F1 by direct interaction (Figure 4A) 
[61]. How then does an E2F1/E2F7 heterodimer bind to DNA and how does E2F7 
dominate E2F1 activity on their target promoter? Overexpression of atypical E2Fs 
inhibits proliferation of fibroblasts in culture [24–29]. Expression of atypical E2Fs 
is upregulated in G1/S transition of fibroblasts because their expression is under the 
control of typical E2Fs. These suggest that atypical E2Fs may function as a negative 
feedback loop to antagonize the function of activator E2Fs in S-phase of the cell 
cycle. However, cells can proliferate in the presence of atypical E2Fs. If they are 
dispensable in the control of cell proliferation, what is the role of atypical E2Fs in 
the physiological setting?
4.2 Atypical E2Fs control endoreplication during mouse development
Mouse atypical E2Fs play crucial roles in endoreplication of placental tropho-
blast giant cells (TGCs) and liver hepatocytes [3, 33, 63]. While the archetypal cell 
cycle proceeds to G2 and M phases after completing DNA replication, endoreplica-
tion is a variant cell cycle, which repeats the cycle of G1 and S phase in the absence 
of intervening mitoses (Figure 4B) [64]. Consequently, endoreplication produces 
mononucleated polyploid cells. Since endoreplication does not permit cells to enter 
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into mitosis, precise control of mitotic cyclin/cdk activity is important to determine 
the initiation and termination of endoreplication.
Loss of E2f1–3 genes results in continuous excess rounds of endoreplication in 
TGCs, while double knock out of E2f7 and E2f8 genes induces a defect in endorep-
lication [3, 63]. Thus, the activator E2F/DP complex promotes exit from endorep-
lication, while atypical E2Fs maintain it. The reduced number of endoreplication 
cycles in E2f7 and E2f8 double mutant TGCs is partially restored by eliminating 
the function of E2f1. These results indicate that DP-independent E2F regulation by 
atypical E2Fs competitively antagonizes the function of DP-dependent E2F regula-
tion by typical E2Fs during endoreplication (Figure 4B). Atypical E2Fs suppresses 
the expression of Cyclin A as well as cdc2, preventing the entry into M phase during 
endoreplication. The transient up-regulation of atypical E2F expression during 
S phase is important to suppress the expression of target genes immediately after 
DNA replication [24–29]. However, the transient accumulation of atypical E2Fs 
does not instruct the timing of initiation and termination of endoreplication. 
The basal level of their expression is changed during tissue development [63]. 
An increase in the basal level of atypical E2Fs expression allows cells to initiate 
endoreplication, while a reduction in basal levels of atypical E2Fs induces cells 
to exit from endoreplication. Thus, a combination of developmental and cell 
cycle cues determines the timing and duration of endoreplication during tissue 
development.
4.3 Endoreplication in fly development
Fly is a model organism that lacks atypical E2f genes in its genome [4, 33]. Yet, 
endoreplication is conducted in cells of multiple tissues including secretory cells of 
Figure 4. 
Atypical E2Fs regulate growth-related E2F target genes by DP-independent mechanism(s) and control 
endoreplication. (A) Possible mechanisms to repress target promoters by atypical E2Fs. Atypical E2Fs repress 
the transcription of their target genes by forming a dimer of atypical E2Fs, or monomer, or binding to an 
activator E2F. (B) Archetypal cell cycle and endoreplication. Four phases (G1, S, G2, M) are proceeded in the 
archetypal cell cycle, while endoreplication repeats G1 and S phases. Atypical E2Fs are induced at G1/S phase 
and antagonize activator E2Fs at S phase in an endoreplication cycle. (C) Endoreplication in fly. Cul4 induces 
an acute degradation of dE2f1 to skip G2 and M phases.
57
Distinct E2F-Mediated Transcriptional Mechanisms in Cell Proliferation, Endoreplication…
DOI: http://dx.doi.org/10.5772/intechopen.82448
salivary glands, subperineural glia of the brain, and ovarian nurse and follicle cells 
[64]. How is cdk activity downregulated immediately after DNA replication in these 
cell types without atypical E2Fs? Instead of atypical E2F-mediated suppression of 
E2F target gene expression, ubiquitin ligase Cul4 induces a rapid degradation of 
dE2f1 during S phase, reducing the expression of E2F target genes including Cyclin 
E and mitotic cyclins (Figure 4C) [65]. Downregulation of Cyclin E/cdk2 activ-
ity during S phase does not allow cell cycle to progress through the G2/M phase 
transition in fly, thereby returning the cell cycle back into G1 phase, resulting in 
endoreplication [66, 67]. These observations imply that organisms lacking atypical 
E2Fs have mechanism(s) to complement their function.
5. The role of E2F1 in apoptosis and tumor suppression
5.1 E2F1 induces apoptosis in a DP-independent manner in mammalian 
fibroblasts
Cultured cell systems also demonstrated that E2F1 can function to induce apop-
tosis [1, 2, 7]. Overexpression of E2F1 induces p53-dependent and p53-dependent 
apoptosis in cultured cells in the absence of survival signals provided by serum 
(Figure 5A). Overexpression of E2F1 induces the expression of Arf, which activates 
p53 through suppression of MDM2 [1, 2, 5, 10, 68]. E2F1 bypasses p53-dependent 
apoptosis by inducing the expression of the p53 homolog, p73 [69, 70]. In contrast 
to control of cell proliferation, DP1 and DP2 are not necessary for E2F1-induced 
apoptosis [13], indicating that E2F1-induced apoptosis is the second model of 
DP-independent E2F function. The function of E2F1 to induce apoptosis is intui-
tively contradictory to its role in promoting cell proliferation. Why does E2F1 
protein have these opposing roles? Since endogenous pRb family proteins are unable 
to suppress the activity of E2F generated by overproduction of E2F, exogenous 
overexpression of E2F1 is supposed to recapitulate deregulated E2F activity that 
results from functional defects in pRb family proteins. Consistent with this theory, 
adenovirus E1A protein, which directly binds to pRb and inhibits its function, 
also induces apoptosis through the Arf-MDM2-p53 pathway in fibroblasts [71–73]. 
Therefore, the role of E2F1-mediated apoptosis has been interpreted as a defensive 
mechanism to protect against and/or counter oncogenic activation of E2F1 that 
induces abnormal proliferation in the context of pRb dysfunction.
5.2 DP-independent regulation of Arf expression by E2F1 in mammalian 
fibroblast
The transcription of the Arf and p73 genes is not increased by endogenous E2F 
activated by serum stimulation in fibroblasts, while the expression of growth-
related E2F target genes is induced (Figure 5B) [10, 12]. One possible explanation 
of the inability of endogenously activated E2F to increase Arf and p73 expression 
is that serum stimulation activates survival signals that specifically counteract the 
induction of apoptotic genes by E2F [74]. Phosphatidylinositol-3 kinase (PI3K) 
signaling inhibits expression of some apoptotic genes, induced by overexpression of 
E2F1, such as AMPKa2, which is involved in metabolism and is not a typical apop-
totic gene [75]. However, it is not clear whether the PI3K signaling regulates these 
genes at the transcriptional level or post-transcriptional level. In addition, PI3K 
signaling does not suppress the induction of Arf gene expression by overexpression 
of E2F1 [76]. Therefore, mechanisms must exist to allow the Arf gene to specifically 
sense and respond to deregulated E2F activity.
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into mitosis, precise control of mitotic cyclin/cdk activity is important to determine 
the initiation and termination of endoreplication.
Loss of E2f1–3 genes results in continuous excess rounds of endoreplication in 
TGCs, while double knock out of E2f7 and E2f8 genes induces a defect in endorep-
lication [3, 63]. Thus, the activator E2F/DP complex promotes exit from endorep-
lication, while atypical E2Fs maintain it. The reduced number of endoreplication 
cycles in E2f7 and E2f8 double mutant TGCs is partially restored by eliminating 
the function of E2f1. These results indicate that DP-independent E2F regulation by 
atypical E2Fs competitively antagonizes the function of DP-dependent E2F regula-
tion by typical E2Fs during endoreplication (Figure 4B). Atypical E2Fs suppresses 
the expression of Cyclin A as well as cdc2, preventing the entry into M phase during 
endoreplication. The transient up-regulation of atypical E2F expression during 
S phase is important to suppress the expression of target genes immediately after 
DNA replication [24–29]. However, the transient accumulation of atypical E2Fs 
does not instruct the timing of initiation and termination of endoreplication. 
The basal level of their expression is changed during tissue development [63]. 
An increase in the basal level of atypical E2Fs expression allows cells to initiate 
endoreplication, while a reduction in basal levels of atypical E2Fs induces cells 
to exit from endoreplication. Thus, a combination of developmental and cell 
cycle cues determines the timing and duration of endoreplication during tissue 
development.
4.3 Endoreplication in fly development
Fly is a model organism that lacks atypical E2f genes in its genome [4, 33]. Yet, 
endoreplication is conducted in cells of multiple tissues including secretory cells of 
Figure 4. 
Atypical E2Fs regulate growth-related E2F target genes by DP-independent mechanism(s) and control 
endoreplication. (A) Possible mechanisms to repress target promoters by atypical E2Fs. Atypical E2Fs repress 
the transcription of their target genes by forming a dimer of atypical E2Fs, or monomer, or binding to an 
activator E2F. (B) Archetypal cell cycle and endoreplication. Four phases (G1, S, G2, M) are proceeded in the 
archetypal cell cycle, while endoreplication repeats G1 and S phases. Atypical E2Fs are induced at G1/S phase 
and antagonize activator E2Fs at S phase in an endoreplication cycle. (C) Endoreplication in fly. Cul4 induces 
an acute degradation of dE2f1 to skip G2 and M phases.
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salivary glands, subperineural glia of the brain, and ovarian nurse and follicle cells 
[64]. How is cdk activity downregulated immediately after DNA replication in these 
cell types without atypical E2Fs? Instead of atypical E2F-mediated suppression of 
E2F target gene expression, ubiquitin ligase Cul4 induces a rapid degradation of 
dE2f1 during S phase, reducing the expression of E2F target genes including Cyclin 
E and mitotic cyclins (Figure 4C) [65]. Downregulation of Cyclin E/cdk2 activ-
ity during S phase does not allow cell cycle to progress through the G2/M phase 
transition in fly, thereby returning the cell cycle back into G1 phase, resulting in 
endoreplication [66, 67]. These observations imply that organisms lacking atypical 
E2Fs have mechanism(s) to complement their function.
5. The role of E2F1 in apoptosis and tumor suppression
5.1 E2F1 induces apoptosis in a DP-independent manner in mammalian 
fibroblasts
Cultured cell systems also demonstrated that E2F1 can function to induce apop-
tosis [1, 2, 7]. Overexpression of E2F1 induces p53-dependent and p53-dependent 
apoptosis in cultured cells in the absence of survival signals provided by serum 
(Figure 5A). Overexpression of E2F1 induces the expression of Arf, which activates 
p53 through suppression of MDM2 [1, 2, 5, 10, 68]. E2F1 bypasses p53-dependent 
apoptosis by inducing the expression of the p53 homolog, p73 [69, 70]. In contrast 
to control of cell proliferation, DP1 and DP2 are not necessary for E2F1-induced 
apoptosis [13], indicating that E2F1-induced apoptosis is the second model of 
DP-independent E2F function. The function of E2F1 to induce apoptosis is intui-
tively contradictory to its role in promoting cell proliferation. Why does E2F1 
protein have these opposing roles? Since endogenous pRb family proteins are unable 
to suppress the activity of E2F generated by overproduction of E2F, exogenous 
overexpression of E2F1 is supposed to recapitulate deregulated E2F activity that 
results from functional defects in pRb family proteins. Consistent with this theory, 
adenovirus E1A protein, which directly binds to pRb and inhibits its function, 
also induces apoptosis through the Arf-MDM2-p53 pathway in fibroblasts [71–73]. 
Therefore, the role of E2F1-mediated apoptosis has been interpreted as a defensive 
mechanism to protect against and/or counter oncogenic activation of E2F1 that 
induces abnormal proliferation in the context of pRb dysfunction.
5.2 DP-independent regulation of Arf expression by E2F1 in mammalian 
fibroblast
The transcription of the Arf and p73 genes is not increased by endogenous E2F 
activated by serum stimulation in fibroblasts, while the expression of growth-
related E2F target genes is induced (Figure 5B) [10, 12]. One possible explanation 
of the inability of endogenously activated E2F to increase Arf and p73 expression 
is that serum stimulation activates survival signals that specifically counteract the 
induction of apoptotic genes by E2F [74]. Phosphatidylinositol-3 kinase (PI3K) 
signaling inhibits expression of some apoptotic genes, induced by overexpression of 
E2F1, such as AMPKa2, which is involved in metabolism and is not a typical apop-
totic gene [75]. However, it is not clear whether the PI3K signaling regulates these 
genes at the transcriptional level or post-transcriptional level. In addition, PI3K 
signaling does not suppress the induction of Arf gene expression by overexpression 
of E2F1 [76]. Therefore, mechanisms must exist to allow the Arf gene to specifically 
sense and respond to deregulated E2F activity.
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We have approached this issue by investigating mechanisms of how E2F regu-
lates Arf gene expression in human fibroblast [10, 13]. Analysis of Arf promoter 
regulation has revealed the following points. (i) the pRb/E2F/DP complex does 
not actively suppress the Arf promoter during the cell cycle (Figure 5C). (ii) The 
Arf promoter is very sensitive to deregulated E2F activity, but not to E2F activity 
induced by serum stimulation. (iii) E2F1 regulation of the Arf promoter does not 
require DP. (iv) The regulation is mediated through a non-canonical E2F bind-
ing site, EREA (Figure 5C). The sequence of EREA is highly conserved in the Arf 
promoters in human and mouse and an isolated EREA reporter construct from the 
mouse Arf promoter showed similar activity in response to serum stimulation and 
overexpression of E2F1. Thus, E2F regulation of EREA may be shared between 
mouse and human [10]. Our finding raised a new question of how E2F1 binds to 
EREA. In vitro studies showed that, while E2F1 alone is able to bind to a canonical 
E2F binding site, the presence of DP1 drastically enhances E2F1 binding affinity to 
this DNA element. In contrast, the presence of DP does not impact E2F1 binding to 
EREA. Since the presence of DP does not interfere with E2F1 binding to the EREA, 
the E2F/DP complex perhaps binds to EREA utilizing only the E2F DBD. In general, 
a transcription factor works in combination or acts synergistically with a functional 
partner protein. Thus, there may be specific factor(s) that cooperatively function 
with E2F1 to regulate EREA.
In parallel to our study, Hallstrom et al. reported different mechanisms of 
regulation of E2F1-induced apoptosis [74, 77]. They found that (i) The MB domain 
determines specificity of E2F1 to induce apoptosis. A chimeric E2F1 mutant 
containing E2F3 MB loses the ability to induce apoptosis, while insertion of the 
E2F1 MB domain into E2F3 confers the ability to induce apoptosis. (ii) E2F1 binds 
Figure 5. 
E2F1 regulation of Arf gene transcription and apoptosis in Rb-deficiency. (A) Schematic view of E2F1-induced 
apoptosis. E2F1 induces apoptosis through p53-dependent and -independent mechanisms. (B) Arf promoter activity 
during the cell cycle. Black line indicates the activity of the wild-type promoter of growth-related E2F target genes. 
Dashed black line indicates the activity of canonical E2F binding site mutant promoter in growth-related E2F 
target genes. Red line indicates the activity of the Arf promoter. (C) E2F regulation of the Arf promoter in normal 
cell proliferation and in the context of deregulated E2F activity in response to dysfunction of pRb.
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to Jab1, a subunit of the COP9 signalosome (CSN), through its MB domain. The 
E2F1-Jab1 interaction is specific to E2F1 because the amino acid sequence of MB 
domain varies among individual E2F proteins. (iii) Jab1 enhances E2F1-indued acti-
vation of p53 and apoptosis. (iv) Jab1 enhances induction of Arf gene expression by 
overexpression of E2F1. (v) Jab1 binds to the Arf promoter [78]. These are indirect 
evidence, but suggest that Jab1 contributes to activation of Arf gene transcription 
by E2F1, leading us to postulate that the EREA plays a role in Jab1 binding to the Arf 
promoter. Further investigation will be required to reveal details of mechanisms 
underlying E2F regulation of Arf gene expression and apoptosis.
5.3 Arf suppresses tumorigenesis in the Rb mutant mouse
Homozygous mutation of the Rb gene induces ectopic proliferation and apopto-
sis in multiple tissues of mouse embryos [3, 79]. These phenotypes are rescued by 
removing E2f1 gene function [80], suggesting that pRb regulates E2F activity and 
deregulated E2F1 induces apoptosis in vivo. Ablation of the Arf gene does not sup-
press the apoptotic phenotype in Rb homozygous mutant embryos [81], indicating 
that E2F1 induces apoptosis through Arf-independent mechanisms in particular cell 
types. The Rb gene is one of the most prominent tumor suppressor genes and loss of 
pRb function is observed in wide variety of human cancers [5]. Heterozygous muta-
tion predicts retinoblastoma and osteoblastoma in human [5]. These observations 
suggest that E2F1-induced Arf may counteract tumorigenesis in Rb mutant cells. 
In a mouse model, heterozygous mutation of Rb typically produced pituitary and 
thyroid tumors, which is used in study of tumor suppressive function of Rb in vivo 
[79]. In these tumors, wild-type Rb allele is also lost during tumor formation and 
loss of E2f1 suppresses tumorigenesis in heterozygous Rb mutant mice [82], indicat-
ing that E2F1 is deregulated to induce abnormal proliferation in these tumor cells. 
In addition, because the tumor phenotype in pituitary and thyroid of Rb heterozy-
gous mutant mouse is exacerbated by loss of Arf [81], it is likely that deregulated 
E2F1 activity counteracts tumor formation through inducing Arf in these tumors. 
Rb−/+; Arf−/− compound mutant mice develop pituitary gland lesions earlier than 
Rb−/+ and Rb−/+; p53−/− [81]. Therefore, Arf should function independently of p53 to 
suppress tumor formation in the pituitary and thyroid glands of Rb mutant mice.
5.4 E2F-induced apoptosis in fly requires DP
Overexpression of de2f1 or homozygous mutation of rbf1 induces apoptosis 
in multiple tissues in the fly [4, 83], indicating that consistent with vertebrates, 
deregulation of dE2f1 induces cell death in fly. However, there are two inconsistent 
observations. Firstly, dE2f1 requires dDP to induce apoptosis [4, 84, 85]. Secondly, 
dE2f1-induced apoptosis is primarily independent of p53 [86]. The role of fly p53 in 
apoptosis is not as predominant as that of mammalian p53 and the Arf gene does 
not exist in the fly genome. Mechanisms of both E2F1-induced and p53-dependent 
apoptosis, and interactions between them, may have been modified and adapted 
during the process of evolution.
6. Conclusion and perspective
In this chapter, we considered multiple roles of E2F transcription factor by intro-
ducing three distinct mechanisms of E2F-mediated transcription. The classic model 
of the E2F/DP complex explains how the heterodimeric complex regulates growth-
related E2F target genes by collaborating with pRb family proteins during the cell 
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We have approached this issue by investigating mechanisms of how E2F regu-
lates Arf gene expression in human fibroblast [10, 13]. Analysis of Arf promoter 
regulation has revealed the following points. (i) the pRb/E2F/DP complex does 
not actively suppress the Arf promoter during the cell cycle (Figure 5C). (ii) The 
Arf promoter is very sensitive to deregulated E2F activity, but not to E2F activity 
induced by serum stimulation. (iii) E2F1 regulation of the Arf promoter does not 
require DP. (iv) The regulation is mediated through a non-canonical E2F bind-
ing site, EREA (Figure 5C). The sequence of EREA is highly conserved in the Arf 
promoters in human and mouse and an isolated EREA reporter construct from the 
mouse Arf promoter showed similar activity in response to serum stimulation and 
overexpression of E2F1. Thus, E2F regulation of EREA may be shared between 
mouse and human [10]. Our finding raised a new question of how E2F1 binds to 
EREA. In vitro studies showed that, while E2F1 alone is able to bind to a canonical 
E2F binding site, the presence of DP1 drastically enhances E2F1 binding affinity to 
this DNA element. In contrast, the presence of DP does not impact E2F1 binding to 
EREA. Since the presence of DP does not interfere with E2F1 binding to the EREA, 
the E2F/DP complex perhaps binds to EREA utilizing only the E2F DBD. In general, 
a transcription factor works in combination or acts synergistically with a functional 
partner protein. Thus, there may be specific factor(s) that cooperatively function 
with E2F1 to regulate EREA.
In parallel to our study, Hallstrom et al. reported different mechanisms of 
regulation of E2F1-induced apoptosis [74, 77]. They found that (i) The MB domain 
determines specificity of E2F1 to induce apoptosis. A chimeric E2F1 mutant 
containing E2F3 MB loses the ability to induce apoptosis, while insertion of the 
E2F1 MB domain into E2F3 confers the ability to induce apoptosis. (ii) E2F1 binds 
Figure 5. 
E2F1 regulation of Arf gene transcription and apoptosis in Rb-deficiency. (A) Schematic view of E2F1-induced 
apoptosis. E2F1 induces apoptosis through p53-dependent and -independent mechanisms. (B) Arf promoter activity 
during the cell cycle. Black line indicates the activity of the wild-type promoter of growth-related E2F target genes. 
Dashed black line indicates the activity of canonical E2F binding site mutant promoter in growth-related E2F 
target genes. Red line indicates the activity of the Arf promoter. (C) E2F regulation of the Arf promoter in normal 
cell proliferation and in the context of deregulated E2F activity in response to dysfunction of pRb.
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to Jab1, a subunit of the COP9 signalosome (CSN), through its MB domain. The 
E2F1-Jab1 interaction is specific to E2F1 because the amino acid sequence of MB 
domain varies among individual E2F proteins. (iii) Jab1 enhances E2F1-indued acti-
vation of p53 and apoptosis. (iv) Jab1 enhances induction of Arf gene expression by 
overexpression of E2F1. (v) Jab1 binds to the Arf promoter [78]. These are indirect 
evidence, but suggest that Jab1 contributes to activation of Arf gene transcription 
by E2F1, leading us to postulate that the EREA plays a role in Jab1 binding to the Arf 
promoter. Further investigation will be required to reveal details of mechanisms 
underlying E2F regulation of Arf gene expression and apoptosis.
5.3 Arf suppresses tumorigenesis in the Rb mutant mouse
Homozygous mutation of the Rb gene induces ectopic proliferation and apopto-
sis in multiple tissues of mouse embryos [3, 79]. These phenotypes are rescued by 
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during the process of evolution.
6. Conclusion and perspective
In this chapter, we considered multiple roles of E2F transcription factor by intro-
ducing three distinct mechanisms of E2F-mediated transcription. The classic model 
of the E2F/DP complex explains how the heterodimeric complex regulates growth-
related E2F target genes by collaborating with pRb family proteins during the cell 
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cycle [1–5]. There is no doubt that the pRb/E2F/DP pathway instructs both entry into 
and exit from the cell cycle. However, recent studies revealed that cells have comple-
mentary mechanisms in control of cell cycle progression at the G1/S phase transition. 
Future studies should address the mechanisms, by which cells can control the exit 
from the cell cycle in the absence of the pRB/E2F/DP complex. The classic E2F/DP 
model is not sufficient to explain all function of E2F family proteins. Two additional 
mechanisms, described above, at least partly fill that knowledge gap. Atypical E2Fs 
play a crucial role in endoreplication by antagonizing the function of activator E2Fs in 
DP-independent and Rb-independent manners [3, 33, 63]. In addition to their role in 
endoreplication, atypical E2Fs may also mediate tumor suppression in multiple tissues 
including liver and skin [87, 88]. How they function in suppressing tumorigenesis is 
an important question for future studies. E2F1 also functions via DP-independent 
mechanisms, which mediate tumor suppression via regulation of apoptotic genes 
including Arf [13]. In addition to modulating tumor suppression, these E2F1 path-
ways may have a role in restricting the plasticity of cell fate in differentiated cells. 
Overexpression of four transcription factors (Oct4, Sox2, c-Myc and klf4) reverts 
the competence of fibroblast to the level of pluripotent embryonic stem cells [89]. 
The efficiency of this reprograming is restricted by the pRb-p53 pathway [90, 91]. 
E2F-dependent transcription of Arf, or regulation of p53, may be involved in the 
mechanism to restrict the plasticity of cell fate in fibroblasts. In addition, Rb and Arf 
contribute to limit the reversion of myocytes to myoblasts in regeneration of muscle 
[92]. These possibilities merit further investigation, and discoveries of new mecha-
nisms of E2F regulation of its target genes will open a new paradigm to understand 
the diverse roles of E2F transcription factor families.
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